OXOSTEROLS FOR ACTIVATION OF
HEDGEHOG SIGNALING:
OSTEOINDUCTION, ANTIADIPOSEGENESIS,
AND WNT SIGNALING

Inventors: Farhad Parhami, Los Angeles, CA
Michael E. Jung, Los Angeles, CA (US); Khandilinh Nguyen, Los Angeles, CA (US); Dongwon Yoo, Los Angeles, CA (US); Woo-Kyun Kim, Los Angeles, CA (US)

Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Oakland, CA (US)

Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 773 days.
This patent is subject to a terminal disclaimer.

Appl. No.: 12/745,888
PCT Filed: Dec. 3, 2008
PCT No.: PCT/US2008/013319
PCT Pub. No.: WO2009/073186
PCT Pub. Date: Jun. 11, 2009

Prior Publication Data

Related U.S. Application Data
Provisional application No. 60/996,729, filed on Dec. 3, 2007.

Int. Cl.
A61K 63/00 (2006.01)
A61K 31/575 (2006.01)
A61K 45/06 (2006.01)

US. Cl.
CPC A61K 31/575 (2013.01); A61K 45/06 (2013.01)

Field of Classification Search
CPC A61K 31/575; A61K 45/06; A61K 2300/00
USPC 424/93.7, 676; 514/182, 11.8, 8.6, 8.8, 514/8.5, 171, 8.9; 435/375, 377, 552/546, 556; 540/120
See application file for complete search history.

References Cited
U.S. PATENT DOCUMENTS
4,559,157 A 12/1985 Smith et al.

4,608,392 A 8/1986 Jacout et al.
4,820,508 A 4/1989 Wortzman
4,938,949 A 7/1990 Borch et al.
4,961,222 A 10/1990 Shroot et al.
4,992,478 A 2/1991 Gerna
5,166,320 A 11/1992 Wu et al.
5,183,815 A 2/1993 Sani et al.
5,219,940 A 6/1993 Miller et al.
5,268,641 A 2/1994 Rotzman
5,929,062 A 7/1999 Haines
6,017,904 A 1/2000 Reed et al.
6,177,420 B1 1/2001 Lemehuis et al.
6,184,215 B1 2/2001 Elias et al.
6,316,503 B1 11/2001 Li et al.
6,420,353 B1 7/2002 Lathe et al.
6,518,262 B1 2/2003 Leysen et al.
6,586,189 B2 7/2003 Forman
6,893,830 B1 5/2005 Janowski et al.
6,906,069 B1 6/2005 Li et al.
7,000,450 B1 6/2006 Tabin et al.
200400716423 A1 9/2004 Paralkar
20050095677 A1 5/2005 Li et al.
200600251735 A1 11/2006 Parhami
200600270645 A1 11/2006 Parhami

FOREIGN PATENT DOCUMENTS
DE 1020402822 3/2006

OTHER PUBLICATIONS
Nagahisa et al. (J. Biol. Chem., 1983, 258, 6721-6723).*
Burstein et al. (Steroids, 1969, 399-412).*
RN102814-21-1 (available Jun. 21, 1986), corresponding to (5S)-(3S)-
(3S)-10,13-dimethyl-2,3,4,7,8,10,11,12,13,14,15,16,17-tetrahydroxy-1H-
pyrido[1,2-a]phenanthren-17-yl)-2-methylhectane-1,3-diol.*
RN135873-40-4 (available Aug. 30, 1991), corresponding to
(5-phenylpento)magnesium bromide.*

Primary Examiner—Jeffrey S Lundgren
Assistant Examiner—Ibrahim D Bori
(74) Attorney, Agent, or Firm—Mintz Levin Cohn Ferris Glosky and Popeo, PC.

ABSTRACT
Synthetic oxosterols can be made and can be used for the treatment of bone disorders, obesity, cardiovascular disorders, and neurological disorders.

14 Claims, 26 Drawing Sheets
(56) References Cited
U.S. PATENT DOCUMENTS

2010/0012030 A1 1/2010 Todd et al.

FOREIGN PATENT DOCUMENTS

GB 806970 A 5/1961
JP 3000-56030 A 2/2002
WO 2006/012920 A2 2/2006
WO 2008/011071 A2 1/2008
WO 2011/006087 A1 1/2011
WO 2012/024581 A2 2/2012
WO 2012/024582 A2 2/2012
ZA 6808005 D 6/1969

OTHER PUBLICATIONS
RN72535-092f Available Nov. 16, 1984, corresponding to (4-methylpent-4-en-1-yl)immagensium bromide.*
References Cited


Day et al., (2005) Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell. 8(5):739-50.


(56) References Cited

OTHER PUBLICATIONS


Silva-Vargas et al., (2005) Beta-catenin and Hedgehog signal strength can specify number and location of hair follicles in adult epidermis without recruitment of bulge stem cells. Dev Cell. 9(1):121-31.
Kim, S. et al., “Identification of Two Brassinosteroids from the Cambial Region of Scots Pine (Pinus silvestris) by Gas Chromato-
ISR from PCT/US2011/025064 mailed Nov. 9, 2011.
Ciobanu, L. et al., “Synthesis and steroid sulphatase inhibitory activity of C19- and C21-steroidal derivatives bearing a benzy1-
Abe et al., “Effects of bisphosphonates on osteoclastogenesis in RAW264.7 cells,” 2012, International Journal of Molecular Medi-
References Cited

References Cited


English Adapted Provided Only.


References Cited

OTHER PUBLICATIONS


* cited by examiner
FIG. 1A
FIG. 1B
FIG. 1C
FIG. 2E
Oxysterols

Hedgehog Pathway Signaling

Non-canonical Wnt Pathway Signaling (Dkk-1-Inhibitable & B-catenin/TCF/Lef Independent)

PI3-kinase Inhibitors

Regulation of ALP, OCN, Wif-1, & Mineralization

PI3-kinase Inhibitors

Regulation of ALP, Nkd2, Wif-1, & Mineralization

FIG. 8
FIG. 9
FIG. 10

Relative mRNA Expression (Fold over Control)

BSP Expression
**FIG. 11**

Osteocalcin

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Relative Expression (Fold Over Control)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>0</td>
</tr>
<tr>
<td>Oxy28(2.5)</td>
<td>1</td>
</tr>
<tr>
<td>Oxy28(5)</td>
<td>2</td>
</tr>
<tr>
<td>Oxy42(2.5)</td>
<td>5</td>
</tr>
<tr>
<td>Oxy42(5)</td>
<td>10</td>
</tr>
<tr>
<td>Oxy49(2.5)</td>
<td>15</td>
</tr>
<tr>
<td>Oxy49(5)</td>
<td>20</td>
</tr>
</tbody>
</table>

**FIG. 12**

Adipocytes/Field

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Adipocytes/Field</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>0</td>
</tr>
<tr>
<td>Tro</td>
<td>50</td>
</tr>
<tr>
<td>Tro+Oxy28</td>
<td>20</td>
</tr>
<tr>
<td>Tro+Oxy49</td>
<td>10</td>
</tr>
<tr>
<td>Oxy28</td>
<td>0</td>
</tr>
<tr>
<td>Oxy49</td>
<td>0</td>
</tr>
</tbody>
</table>
FIG. 14
FIG. 15

![Graph showing relative luciferase activity (fold over vehicle) for control, Oxy34, and Shh conditions. The graph includes bars for pGL3b and pGL3b-8XGli.](image-url)
1 OXysterOLS FOR ACTIVATION OF HEDGEHOG SIGNALING, OSTEoINDUCTION, ANTIADiPOGENESIS, AND WNT SIGNALING

This application is a U.S. National Stage of International Application No. PCT/US2008/013319, filed Dec. 3, 2008, which claims the benefit of U.S. Provisional Application No. 60/996,729, filed Dec. 3, 2007, all of which are hereby incorporated by reference herein in their entirety.

This invention was made with Government support of NIH/NIAMS grant RO1AR050426, awarded by the National Institutes of Health. The government has certain rights in the invention.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Sep. 13, 2010, is named 58086288.txt and is 3,147 bytes in size.

BACKGROUND

Oxysterols form a large family of oxygenated derivatives of cholesterol that are present in the circulation, and in human and animal tissues. Oxysterols that have been identified in human plasma to date include 7α-hydroxycholesterol, 24S-hydroxycholesterol, and 4α- and 4β-hydroxycholesterol, which are present at concentrations ranging from 5-500 ng/ml. These oxysterols have a variety of half-lives in circulation ranging from 0.5-60 hours, and their levels can be altered by aging, drug interventions, and disease processes. Oxysterols may be formed either by autooxidation, as a secondary hydroporoc of lipid peroxidation, or by the action of specific monoxygenases, most of which are members of the cytochrome P450 family of enzymes. Examples of these enzymes are cholesterol 7α-hydroxylase (CYP7A1) that forms 7α-hydroxycholesterol, cholesterol 25-hydroxylase that forms 25-hydroxycholesterol, cholesterol 24S-hydroxylase (CYP46) that forms 24S-hydroxycholesterol, and others. In addition, oxysterols may be derived from the diet. Cytochrome P450 enzymes are also involved in the further oxidation of oxysterols and their metabolism into active or inactive metabolites that leads to their eventual removal from the system. Certain oxysterols can have potent effects on cholesterol metabolism. Oxysterols have been found to be present in atherosclerotic lesions. Oxysterols may play a role in various physiologic processes, such as cellular differentiation, inflammation, apoptosis, and steroid production.

Osteoporosis and its complications cause morbidity and mortality in the aging population, and can result from increased bone resorption by osteoclasts in parallel with decreased bone formation by osteoblasts.

2 SUMMARY

In an embodiment according to the invention, a compound has the formula

![Formula](image)

q can be a single bond or a double bond; and t can be a single bond or a double bond. At least one of q and t can be a single bond. M can be hydrogen (—H), hydroxy (—OH), formoxy (—O(O—C—H)), acetoxyl (—O(O—C—H)), acyloxy (—O(C—O—alkyl), oxygen (—O), alkxy (—O-alkyl), sulfhydryl (—SH), alkylthio (—S-alkyl), amino (—NH2), methylamino (—NHCH3), alkylamino (—NH-alkyl), formamido (—NH(C—O—alkyl), acetamido (—NHCH2—), and alkylamido (—NH(C—O—alkyl), with alkyl of from 1 to 6 carbons. When M is oxygen, then t can be a double bond and q can be a single bond. When M is hydroxy, hydrogen, or acetoxyl, then t can be a single bond. E can be alkyl of from 1 to 6 carbons, for example, methyl. Rj can be alkane of from 1 to 6 carbons, alkane of from 2 to 6 carbons, alkynyl of from 2 to 6 carbons, aralkyl of from 4 to 12 carbons, aralkane from 5 to 12 carbons, aralkane of from 5 to 12 carbons, halogen-substituted aralkyl of from 4 to 12 carbons, halogen-substituted aralkane from 5 to 12 carbons, alkyl-substituted aralkyl of from 5 to 12 carbons, alkyl-substituted aralkane from 5 to 12 carbons, alkyl-substituted aralkane from 6 to 18 carbons, alkyl-substituted aralkane of from 6 to 18 carbons, hydroxy-substituted alkyl of from 1 to 6 carbons, hydroxy-substituted alkane of from 2 to 6 carbons, or hydroxy-substituted alkane of from 2 to 6 carbons. For example, Rj can be phenylalkane of from 7 to 12 carbons, halogen-substituted phenylalkane of from 7 to 12 carbons, phenyl-substituted alkane of from 8 to 12 carbons, phenyl-substituted alkyl of from 8 to 12 carbons, phenyl-substituted alkane of from 5 to 11 carbons, or phenyl-substituted alkane of from 5 to 11 carbons, or phenyl-substituted alkane of from 5 to 11 carbons.

In an embodiment according to the invention, the compound has an activity when contacted with a human or animal cell of stimulating osteoblastic differentiation, inhibiting adipocyte differentiation, stimulating cartilage formation, stimulating hair growth, and/or stimulating angiogenesis.

For example, when q is a double bond, M is hydrogen, and E is methyl, then Rj can be other than ethyl, n-propyl, 4-methylpentyl, 4-methyl-3-pentenyl, 4-methyl-4-pentenyl, and 1-hydroxy-4-methylpentyl. For example, when q is a double bond and M is hydrogen, then Rj can be other than methylbenzyl.

For example, when q is a single bond, M is hydrogen, and E is methyl, then Rj can be other than 4-methylpentyl, vinyl, 1-hydroxy-4-methylpentyl, 3-hydroxy-3-methylbutyl, 4-hydroxy-4-methylpentyl, 1,4-dihydroxy-4-methylpentyl, 1,5-
dihydroxy-4-methylpentyl, and 2-phenylethenyl. For example, when q is a single bond, M is hydroxy, and E is methyl, then R₂ can be other than 4-methyl-pentyl and 4-methyl-3-pentenyl. For example, when q is a double bond, M is hydrogen, and E is methyl, then R₂ can be other than ethyl, n-propyl, n-butyl, n-pentyl, t-butyl, 1-methylpropyl, 3-methylbutyl, 3-methylpentyl, 4-methylpentyl, vinyl, allyl, 1-propenyl, 4-propenyl-3-pentenyl, 4-methyl-4-pentenyl, 3-hydroxy-3-methylbutyl, 4-hydroxy-3-methylbutyl, 4-hydroxy-4-methylpentyl, 1-hydroxy-4-methylpentyl, and 1,4-dihydroxy-4-methylpentyl, and 1-(2-pyridinyl)ethyl. For example, when q is a double bond, M is hydrogen, and E is 4-methylpentyl, then R₂ can be other than hydroxymethyl. For example, when q is a double bond and M is hydrogen, then R₂ can be other than methylenzyl. For example, when t is a double bond, M is oxygen, and E is methyl, then R₂ can be other than 4-methyl-pentyl and 1-hydroxy-4-pentylpentyl.

For example, when q is a double bond, M is hydrogen, and R₂ is alkane or alkene, then R₂ can be

\[
\begin{align*}
\text{CH}_3 & \quad \text{CH}_3 \\
\text{CH}_2 & \quad \text{CH}_2 \\
\text{CH}_2 & \quad \text{CH}_2
\end{align*}
\]

In an embodiment according to the invention, a compound has the formula

\[
\begin{align*}
\text{CH}_3 & \quad \text{OH} \\
\text{HO} & \quad \text{R}_2 \\
\text{HO} & \quad \text{R}_2
\end{align*}
\]

In an embodiment according to the invention, q is a single bond and t is a single bond. M can be hydroxy, and E can be methyl. R₂ can be R₂-R₄, with R₂ being bonded to the two sequentially bonded carbons bonded to the 5-carbon ring. R₄ can be alkane of from 1 to 6 carbons, alkene of from 2 to 6 carbons, or alkyne of from 2 to 6 carbons. R₄ can be phenyl or thiophene.

In an embodiment according to the invention, q is a double bond. M can be hydrogen, and E can be methyl. R₂ can be R₂-R₄, with R₂ being bonded to the two sequentially bonded carbons bonded to the 5-carbon ring. R₄ can be alkane of from 1 to 6 carbons, alkene of from 2 to 6 carbons, or alkyne of from 2 to 6 carbons. R₂ can be hydrogen, phenyl, halogen-substituted phenyl, thiophene, or hydroxy.
bition of adipocyte differentiation, adipocyte morphogenesis, and/or adipocyte proliferation.

A method for treating a subject suffering from a bone disorder, osteoporosis, osteopetrosis, osteoarthritis, a bone fracture, obesity, xanthoma formation, a cardiovascular disorder, atherosclerosis, myocardial infarction, peripheral vascular disease, stroke, and/or alopecia, according to the invention, can include administering to the subject an effective amount of a bioactive composition or pharmaceutical composition comprising an oxysterol compound according to the invention. The subject can be administered the bioactive composition or pharmaceutical composition at a therapeutically effective dose in an effective dosage form at a selected interval to increase bone mass. The subject can be administered the bioactive composition or pharmaceutical composition at a therapeutically effective dose in an effective dosage form at a selected interval to ameliorate the symptoms of osteoporosis. A subject can be treated, for example, to induce bone formation, by harvesting mammalian mesenchymal stem cells, treating the mammalian mesenchymal cells with an oxysterol compound according to the invention to induce osteoblastic differentiation of the cells, and administering the differentiated cells to the subject.

A method for treating a subject suffering from a neurological disorder, according to the invention, can include administering to the subject an effective amount of a bioactive composition or pharmaceutical composition comprising an oxysterol compound according to the invention.

In an embodiment according to the invention, an implant for use in a human or animal body includes a substrate having a surface. The surface of the implant can include a bioactive composition or pharmaceutical composition comprising an oxysterol compound according to the invention in an amount sufficient to induce bone formation in the surrounding bone tissue.

**BRIEF DESCRIPTION OF DRAWINGS**

**FIG. 1** presents the chemical structures of oxysterol compounds designated as Oxy22, Oxy26, Oxy27, Oxy28, Oxy39, Oxy40, Oxy41, Oxy42, Oxy48, Oxy49, Oxy50, Oxy34, Oxy35, Oxy38, Oxy50, Oxy51, Oxy52, and Oxy53.

**FIG. 2** shows how the LRP5/6 inhibitor, Dickkopf-1 (Dkk-1), inhibits oxysterol-induced osteogenic differentiation in marrow stromal cells.

**FIG. 3** shows the effect of osteogenic oxysterols on TCF/LEF transcriptional activity in marrow stromal cells.

**FIG. 4** shows how osteogenic oxysterols differentially regulate Wnt target gene expression in marrow stromal cells.

**FIG. 5** shows the effects of various inhibitors on oxysterol-induced Nkd2 and Wnt1 expression in marrow stromal cells.

**FIG. 6** shows how Wnt3a conditioned medium inhibits oxysterol-induced alkaline phosphatase activity in marrow stromal cells.

**FIG. 7** shows how oxysterol-induced osteogenesis is mediated by the PI3-Kinase pathway in marrow stromal cells.

**FIG. 8** shows molecular mechanisms by which osteogenic oxysterols induce osteogenic differentiation of marrow stromal cells.

**FIG. 9** shows the effect of various oxysterol molecules on alkaline phosphatase activity in marrow stromal cells.

**FIG. 10** shows the effect of various oxysterol molecules on bone sialoprotein (BSP) expression in marrow stromal cells.

**FIG. 11** shows the effect of various oxysterols on osteocalcin mRNA expression in bone marrow stromal cells.

**FIG. 12** shows the effect of various oxysterols on adipogenesis of bone marrow stromal cells.

**FIG. 13** shows the effect of various oxysterols on adipogenesis of bone marrow stromal cells.

**FIG. 14** shows the effect of Oxy94 and Shh on Gli1 induced reporter activity.

**FIG. 15** shows the effect of Oxy34 and Shh on Gli1 induced reporter activity.

**FIG. 16** shows the effect of various oxysterols on Gli1 and Patched mRNA expression in bone marrow stromal cells.

**FIG. 17** shows the effect of various oxysterols on bone sialoprotein mRNA expression in bone marrow stromal cells.

**FIG. 18** shows the effect of various oxysterols on mineralization of marrow stromal cells.

**DETAILED DESCRIPTION**

Embodiments of the invention are described in detail below. In describing embodiments, specific terminology is employed for the sake of clarity. However, the invention is not intended to be limited to the specific terminology so selected. A person skilled in the relevant art will recognize that other equivalent parts can be employed and other methods developed without parting from the spirit and scope of the invention. All references cited herein are incorporated by reference in their entirety as if each had been individually incorporated. Patent Cooperation Treaty (PCT) international applications published as WO2008/115469, WO2008/082520, WO2007/058281, WO2007/028101, WO2006/110490, WO2005/020928, and WO2004/019864 are hereby incorporated by reference in their entirety.

In this text, “alkyl” can mean a chemical functional group in which an aryl ring is bound to an alkyl group. “Alkenyl” can mean a chemical functional group in which an aryl ring is bound to an alkenyl group. “Aryl” can mean a chemical functional group in which an aryl ring is bound to an aryl group. An “aryl” group can mean a chemical functional group including one or more rings, of which at least one ring is aromatic. The ring or rings may be formed of carbon atoms or may be heterocyclic. Examples of aryl rings include benzene ring, a naphthalene, pyridine, pyrrole, thiophene, furan, oxazole, thiazole, imidazole, indole, and quinoline. In an embodiment, the aryl ring may be substituted, for example, by halogen, alkyl (e.g., methyl), amine, hydroxy, and/or sulfhydryl.

Oxysterols can play a role in cellular differentiation. Specific oxysterols induce the differentiation of human keratinocytes in vitro, while monocyte differentiation can be induced by the oxysterol 7-ketocholesterol. Differentiation of keratinocytes by oxysterols is mediated by the nuclear hormone receptor, liver X receptor β (LXRβ). LXRα and LXRβ, initially identified as orphan nuclear receptors, act as receptors for oxysterols. However, many of the effects of oxysterols are mediated by LXR-independent mechanisms. These include their effects on mesenchymal cells, since activation of LXR by specific LXR ligands inhibited, rather than stimulated, the osteogenic differentiation of mesenchymal cells. Furthermore, MSC derived from LXR null mice were able to respond to osteogenic oxysterols as well as their wild type counterparts. Additional oxysterol binding proteins have been reported that can regulate the activity of signaling molecules such as mitogen-activated protein kinase (MAPK).
Hedgehog molecules can play roles in a variety of processes including tissue patterning, mitogenesis, morphogenesis, cellular differentiation and embryonic developments. In addition to its role in embryonic development, hedgehog signaling can play a role in postnatal development and maintenance of tissue/organ integrity and function. Hedgehog signaling can be important during skeletogenesis as well as in the development of osteoblasts in vitro and in vivo. Hedgehog signaling can inhibit adipogenesis when applied to pluripotent mesenchymal cells, C3H-10T 1/2.

Hedgehog signaling can involve a complex network of signaling molecules that includes plasma membrane proteins, kinases, phosphatases, and factors that facilitate the shuffling and distribution of hedgehog molecules. Production of hedgehog molecules from a subset of producing/growing cells involves its synthesis, autophosphorylation and lipid modification. Lipid modification of hedgehog, which may be essential for its functionality, can involve the addition of a cholesterol molecule to the C-terminal domain of the auto-cleaved hedgehog molecule and palmitoylation at its N-terminal domain. Additional accessory factors can help shuttle hedgehog molecules to the plasma membrane of the signaling cells, release them into the extracellular environment, and transport them to the responding cells.

In the absence of hedgehog molecules, Patched (Ptc), present on the plasma membrane of the responding cells, can keep hedgehog signaling in a silent mode by inhibiting the activity of another plasma membrane associated signal transducer molecule, Smoothened (Smo). In the presence of hedgehog, the inhibition of Smo by Ptc can be alleviated and Smo can transduce the signal for the regulation of transcription of hedgehog-regulated genes. This transcriptional regulation in part can involve the Ci/Gli transcription factors that enter the nucleus from the cytoplasm after an interaction between the members of a complex of accessory molecules that regulate Gli and its conversion from a 75 kDa transcriptional repressor to a 155 kDa transcriptional activator (63).

Pluripotent mesenchymal stem cells found in the bone marrow stroma, also known as bone marrow stromal cells (MSC), have the potential to differentiate into several different cell types including osteoblasts, chondrocytes, myocytes, fibroblasts, and adipocytes (1-3). Regulation of stem cell fate down these various lineages is important for tissue development, homeostasis and repair (4, 5). Osteoporosis is a degenerative disease of the skeleton that generally occurs due to an alteration in bone turnover homeostasis and is characterized by fragile bones and increased susceptibility to bone fractures (6). Decreased bone synthesis due to reduced osteoblast formation and/or activity of progenitor cells, which occurs in parallel with increased adipocyte formation at the expense of osteoblasts, in addition to increased bone resorption from excessive osteoclast formation and/or activity is mechanisms leading to this degenerative disorder (7). In addition to anti-resorptive agents, therapeutic molecules having pro-osteogenic and anti-adipogenic effects on MSC may help intervene with osteoporosis by enhancing bone formation through a shift in the apparent imbalance in cellular differentiation in favor of osteoblasts (8-10).

Oxysterols are products of cholesterol oxidation and are formed in vivo by a variety of cell types including osteoblasts (11, 12). Certain oxysterols, such as 20(S)-hydroxycholesterol (20S), alone or in combination with, 22(S)- or 22(R)-hydroxycholesterol, can be potent inducers of osteogenic differentiation in pluripotent mesenchymal cells such as M2-10B4 (M2) marrow stromal cells and C3H10T1/2 embryonic fibroblasts (13). These oxysterols can induce osteogenic and inhibit adipogenic differentiation of MSCs through activation of the hedgehog signaling pathway, which in turn regulates the master switches that control osteogenic and adipogenic differentiation, namely Runx2 and PPARγ, respectively (14-16). Oxysterols may be able to serve as potential therapeutics for intervention with osteoporosis and other musculoskeletal disorders. Certain mechanisms may play a synergistic and/or cooperative role with hedgehog signaling in mediating the effects of osteogenic oxysterols on MSC differentiation.

Wnts are small (30-46 kDa) lipid-modified secreted glycoproteins that influence many aspects of embryological development, such as cell patterning, proliferation, and stem cell fate determination (17-19). Wnt proteins signal through Frizzled (Fz) molecules, which are a family of seven-pass transmembrane receptors that transduce the signal through either β-catenin-dependent (i.e., canonical β-catenin/TCF/LEF pathway) or independent (i.e., non-canonical Wnt/planar cell polarity and the Wnt/calcium pathways) mechanisms. Activation of the β-catenin-dependent pathway requires the presence of low-density lipoprotein receptor related protein (LRP5/6) (20). Certain Wnts induce osteogenesis, through direct stimulation of Runx2 gene expression (21, 22), and inhibit adipogenesis by inhibition of PPARγ and C/EBPα (23, 24). Furthermore, humans loss of function mutations in the LRP5 gene results in the osteoprogenic disorder osteoporosis-pseudoglioma syndrome (25), whereas gain of function mutations in this same gene results in high bone mass disorders (26). It is possible to specifically inhibit the β-catenin-dependent Wnt signaling pathway using the protein Dickkopf-1 (Dkk-1), which directly binds to and removes LRP5/6 from the cell surface through endocytosis, thereby preventing β-catenin-dependent Wnt signaling from occurring (22, 27). Although classically thought to specifically act as an inhibitor of β-catenin dependent Wnt signaling, several reports have shown the inhibitory effects of Dkk-1 independent of β-catenin (28, 29). Hedgehog and Wnt signaling act synergistically and/or cooperatively in regulating several physiologic and pathologic processes including osteoblast development, and hair follicle morphogenesis (30-33).

The PI3-kinase/Akt pathway is involved in a variety of cellular processes including cell growth, proliferation, survival, metabolism, invasion, angiogenesis, and DNA repair. The PI3-kinase/Akt pathway can play a role in the survival of uncommitted osteoblast precursor cells (34, 35) and in the regulation of osteoblast differentiation and migration (36-38). Akt−/− mice have severely delayed bone development (39), and specific deletion of Akt inhibitor, Pten phosphatase, in osteoblasts results in increased bone density throughout life in mice (40). PI3-kinase/Akt activation may play a direct or synergistic role in mediating the biological effects of hedgehog signaling including cell cycle progression, neuronal and chondrogenic differentiation, and capillary morphogenesis by endothelial cells (41-44).

Certain oxysterols can exert their osteogenic effects through a Dkk-1 inhibitable and PI3-kinase-dependent mechanism(s). Although Dkk-1 is able to block the oxysterol-induced osteogenic differentiation of MSC, oxysterols appear to regulate some but not all targets of Wnt signaling. To improve bone health, osteoprogenitor cells can be targeted in order to stimulate their osteogenic differentiation and bone forming properties through the use of osteoinductive/anabolic factors. Certain naturally-occurring oxysterols have osteoinductive properties, mediated in part through activation of hedgehog signaling in osteoprogenitor cells. In parallel to activating the hedgehog signaling pathway, osteo-
genic osteoclasts can activate the Wnt-related signaling pathway through a Dkk-1-inhibitable and β-catenin independent manner. Bone marrow stromal cells treated with osteoclasts can demonstrate increased expression of osteogenic differentiation markers, along with selective induced expression of Wnt target genes. These osteoclast effects, which can occur in the absence of β-catenin accumulation or TCF/LEF activation, can be inhibited by the hedgehog pathway inhibitor, cyclopamine, and/or by the Wnt pathway inhibitor, Dkk-1. The inhibitors of PI3-Kinase signaling, LY 294002 and wortmanna, can inhibit osteoclast-induced osteogenic differentiation and induction of Wnt signaling target genes. Osteogenic osteoclasts are small molecule modulators of signaling pathways in pluripotent mesenchymal cells that regulate numerous developmental and post-developmental processes.

It has been demonstrated that bone formation in vivo in a rat calvarial defect model can be enhanced when the defects are implanted with a carrier PLOA disc containing osteogenic osteoclasts 20S-hydroxysterol+22S-hydroxycholesterol. This finding demonstrated that osteogenic osteoclasts that induce osteogenic differentiation of osteoprogenitor cells, for example bone marrow stromal cells, in vitro also stimulate osteogenic activity of cells in vivo and bone healing (74).

The osteoclasts presented herein can be useful in creating new therapeutic formulations for induction of bone formation, treatment of osteoporosis, and for other indications. These osteoclasts have a lower cost of synthesis/production as well as better safety and activity profiles than conventional compounds presently used to induce bone formation and treat osteoporosis. Such applications can be based on the ability of these osteoclasts to induce the hedgehog signaling pathway. Certain osteoclasts can target pluripotent cells to induce their lineage specific differentiation into various cell types, for example, osteoblasts, due to the induction of hedgehog signaling in these cells. Mesenchymal stem cells treated with these compounds can show induced expression of markers of osteoblast differentiation.

In this study, osteoclasts have been synthesized and tested in vitro for activation of hedgehog signaling pathway in pluripotent mesenchymal cells and induction of markers of osteogenic differentiation. Certain osteoclasts can inhibit adipogenic differentiation of similar cells and/or can induce Wnt related signaling. The osteoclasts presented herein can be used in therapeutic formulations for various indications including but not limited to induction of local bone formation, treatment of osteoporosis, and anti-obesity applications. Other indications that are applicable based on the hedgehog pathway activating property of these molecules are 1) cardiovascular diseases including, but not limited to, arteriosclerosis, angina pectoris, myocardial infarction, and stroke, 2) hair growth/halopecia, and 3) cartilage formation.

Osteoclasts discussed in this application include those designated as Oxy22, Oxy26, Oxy27, Oxy28, Oxy39, Oxy40, Oxy41, Oxy42, Oxy48, Oxy49, Oxy20, Oxy34, Oxy36, Oxy38, Oxy50, Oxy51, Oxy52, and Oxy53. The chemical structures of these molecules is presented in FIG. 1 (64, 65). At least the following osteoclasts have been identified as osteoinductive: Oxy22, Oxy26, Oxy27, Oxy28, Oxy39, Oxy40, Oxy41, Oxy42, Oxy48, Oxy49, Oxy50, Oxy51, Oxy52, and Oxy53. The osteoinductive properties of these osteoclasts is shown by their ability to induce the expression of various osteoblast differentiation markers, including alkaline phosphatase activity, osteocalcin mRNA expression, and mineralization. These osteoclasts are activators of the hedgehog signaling pathway. These osteoclasts also inhibit adipogenesis of pluripotent cells.

An osteoclast compound according to the invention can have an activity, that is, can induce a biological response, when contacted with a human or animal cell. For example, the cell can be a mesenchymal stem cell or a bone marrow stromal cell. This activity or response can be correlated with stimulating osteoblastic differentiation, inhibiting adipocyte differentiation, stimulating cartilage formation, stimulating hair growth, and/or stimulating angiogenesis. A bioactive composition, for example, a pharmaceutical composition including a pharmaceutically acceptable carrier and an osteoclast compound according to the invention can have an activity, that is, can induce a biological response, when administered to a mammalian cell, for example, a cell in vitro or a cell in a human or an animal. This activity or response can be correlated with stimulating osteoblastic differentiation, inhibiting adipocyte differentiation, stimulating cartilage formation, stimulating hair growth, and/or stimulating angiogenesis. Such an activity or response can arise from stimulation of the hedgehog pathway. For example, such an activity or response of an osteoclast compound according to the invention can be characterized by one or more of the following when the osteoclast compound is administered to a cell, a human, a mammal, or an animal: osteocalcin, Gl1, Patched, bone sialoprotein, Axin2, Cyclin D1, Nkd2, and/or WIF-1 mRNA expression above that observed for a control; adipocyte growth less than that observed for a control (the osteoclast compound according to the invention and any control compound each administered with Trogilazine); Gli induced reporter activity above that observed for a control, TCF/LEF reporter activity above that observed for a control; and/or 4Ca incorporation and/or alkaline phosphatase activity above that observed for a control. The control can be, for example, an untreated cell, in vitro or in a human or animal, such as a mammal. Alternatively, the control can be a cell to which a control compound has been administered. For example, such a control compound can be a vehicle, a pharmaceutically acceptable carrier, a naturally occurring or synthetic osteoclast, and/or another compound. A biological response may be identified via a cell-level laboratory assay, such as an assay discussed herein, including measurements of various types of protein expression and other activity. According to the invention, these biological responses are considered to be “correlated with” desirable tissue-level pharmaceutical effects identified herein, such as stimulating osteoblastic differentiation, inhibiting adipocyte differentiation, stimulating cartilage formation, stimulating hair growth, and/or stimulating angiogenesis. “Above that observed” and “less than that observed” refers to a statistically significant difference, for example, with p<0.05.

The induction of BSP expression may be important for the maximal potency of osteoclasts, such as the Oxy compounds discussed herein, to induce mineralization in cultures of M2-1084 cells. Induction of BSP expression may be important for the osteoinductive property of osteoclast molecules. Based on structure-activity relationship (SAR) studies we performed, for example, experiments discussed herein, it appears that the osteoinductive potential of the osteoclasts may increase when a double bond is added between the 25-carbon and the 27-carbon of 20(S)-hydroxycholesterol. For example, the osteoinductive potential of an osteoclast may be increased if it has a double bond between the 25-carbon and the 27-carbon and/or a hydroxy group pendant from the 6-carbon of the B-ring, such as Oxy49.
Thus, some applications of oxysterols discussed herein include the following. An oxysterol can be used to activate the hedgehog pathway in order to target any cell, organ, or tissue in humans and/or animals for an indication that would benefit from the activation of the hedgehog pathway. An oxysterol can be used to induce systemic bone formation to treat a disorder such as osteoporosis, to induce local bone formation to treat conditions such as non-union fractures, and bone defects of any sort, such as calvarial bone or jaw bone defects in dental applications/implants, and to induce spinal fusion. An oxysterol can be used alone or in combination with one or more bone morphogenetic proteins and other osteoinductive and osteoconductive molecules. A combination of different oxysterols can be used. An oxysterol can be used to inhibit systemic fat formation to treat a condition such as obesity, and can be used to inhibit local fat formation to treat a condition such as a xanthoma. An oxysterol can be used to induce the formation of cartilage, for example, by activating the hedgehog pathway, when used alone or in combination with other inducers of chondrocyte differentiation. For example, the use of an oxysterol to induce the formation of cartilage can be used to treat a condition such as osteoarthritis, the repair of normal wear and tear of joints. An oxysterol can be used to treat a cardiovascular condition, for example, a condition that may benefit from increased hedgehog pathway activity resulting in protective effects on cells of all origin, including neural and vascular, in indications such as, but not limited to, stroke, myocardial infarction, arteriosclerosis, and peripheral vascular disease. An oxysterol can be used to induce new blood vessel formation and/or angiogenesis, for example, by activating the hedgehog pathway. An oxysterol can be used to induce hair growth to treat alopecia. An oxysterol can be used to induce Wnt (Wnt Inhibitory Factor-1) in any cell type of human or animal origin. An oxysterol can be used to activate Wnt pathway related signaling in any cell type of human or animal origin. Oxysterol-Induced Osteogenesis is Inhibited by the Wnt Signaling Inhibitor, Dickkopf-1 (Dkk-1)

We examined the possible role of Wnt signaling in oxysterol-induced osteogenic differentiation of MSC (mesenchymal stem cells) by treating M2 cells with Dkk-1. Several markers of osteogenic differentiation were analyzed, including alkaline phosphatase (ALP) activity, osteocalcin (OCN) mRNA expression, and mineralization. Pre-treatment with Dkk-1 caused a partial but significant inhibition of oxysterol-induced ALP activity in M2 cells (FIG. 2A); Dkk-1 alone had no observed effect. To assess if the observed inhibition of ALP activity using Dkk-1 was specific to oxysterols, we examined the effect of Dkk-1 pre-treatment to treat on other osteoinductive factors, namely sonic hedgehog (Shh) and bone morphogenetic protein-2 (BMP-2). As with oxysterol-induced ALP activity, Dkk-1 pre-treatment partially inhibited Shh-induced ALP activity (FIG. 2B). However, BMP-2-induced ALP activity was only significantly inhibited by using the higher concentration of Dkk-1, and to a lesser extent than that achieved for oxysterol- and Shh-induced ALP activity despite similar levels of ALP activity induction by all three molecules (FIG. 2C). Complete and below baseline level inhibition of oxysterol-induced mineralization in M2 cells pretreated with Dkk-1 was observed (FIG. 2D). Dkk-1 did not inhibit oxysterol-induced OCN mRNA expression in M2 cells (FIG. 2E), and did not inhibit oxysterol-induced Runx2 DNA binding activity assessed by EMSA analysis.

Osteogenic Oxysterols Selectively Regulate Targets of Wnt Signaling

To demonstrate the role of Wnt signaling in oxysterol-induced biological effects in M2 cells, we examined the effects of oxysterols on several markers of Wnt signaling, including TCF/LEF-mediated transcriptional activity, cytosolic accumulation of β-catenin, and induced expression of several known Wnt target genes. Transcriptional activity of TCF/LEF in M2 cells treated with 5 μM SS, 200 ng/ml Shh, or 40 mM lithium chloride (LiCl) was measured using a luciferase reporter containing 4 wild-type or mutant TCF/LEF binding sites (47). No significant change in reporter activity was observed in SS- or Shh-treated cells compared to untreated control cells after 24 hours, whereas the positive control, LiCl, significantly induced TCF/LEF reporter activity (FIG. 3A). Reporter activity was not induced after 48 or 72 hours of treatment with oxysterols or Shh. Similar results were obtained when we used a different TCF/LEF reporter construct containing a Cyclin D1 promoter element, which has a TCF/LEF binding site (48) and was activated by LiCl, but not oxysterols, after 24 hours of treatment (FIG. 3B). LiCl had no effect on pG5.6 basic luciferase control reporter (48). Cytosolic extracts from M2 cells treated for 8, 24, and 48 hours with 5 μM SS showed no significant change in β-catenin levels as measured by Western blot analysis and normalized to β-actin levels.

In addition to the TCF/LEF reporter assays and Western blots of β-catenin described above, we also examined the effect of osteogenic oxysterols on the expression of several genes that are known targets of Wnt signaling, namely Axin2, Cyclin D1, Naked Cuticle 2 (Nkd2) and Wnt Inhibitory factor-1 (Wif-1) (48-52). Results showed no significant change in Axin2 mRNA expression upon treatment of M2 cells with 5 μM SS or 200 ng/ml Shh after 8 and 48 hours, whereas LiCl induced its expression at both time points (FIGS. 4A and 4B). Oxysterols did not significantly induce Cyclin D1 mRNA expression, whereas Shh did cause a small but significant increase in its expression after 8 hours, but not 48 hours, of treatment (FIGS. 4C and 4D). LiCl did not induce the expression of Cyclin D1 in M2 cells at 8 hours and inhibited its baseline expression after 48 hours. mRNA expression of both Nkd2 and Wif-1, which are Wnt target genes that antagonize canonical Wnt signaling (50-52), were significantly induced by oxysterols 6 and 30 fold, respectively, after 48 hours (FIGS. 4E and 4F), but not after 8 hours. Shh treatment induced Wif-1, but not Nkd2 expression (FIGS. 4E and 4F). As anticipated from the inability of Shh to induce Nkd2 expression, the Hh pathway inhibitor, cyclopamine, at concentrations that completely abolished the induced expression of Hh target gene, Patched (Pch), did not inhibit oxysterol-induced Nkd2 expression (FIG. 5A). In contrast, oxysterol-induced Wif1 expression was completely blocked by cyclopamine (FIG. 5B). Oxysterol-induced Nkd2 expression was almost completely inhibited by Dkk-1 (FIG. 5C), whereas oxysterol-induced Wif1 was only minimally inhibited (FIG. 5D). To assess whether Wnt pathway activation might regulate oxysterol-induced Hh pathway activity, we tested the effect of Dkk-1 on oxysterol-induced Pch mRNA expression, and found that Dkk-1 did not inhibit Pch expression (FIG. 5E).

Wnt3a Inhibits Osteogenic Differentiation of M2-10B4 RAW264.7 Cells

To examine the effect of Wnt signaling on osteogenic differentiation of M2 cells, we tested the effect of Wnt3a conditioned medium (CM) on ALP activity compared to control CM (C CM). M2 cells were treated in osteogenic medium for 6 days with either C CM or Wnt3a CM at 1:25, 1:50, or 1:100 dilutions. Spontaneous increase in ALP activity that is normally seen as M2 cells differentiate in
osteogenic medium was inhibited by Wnt3a CM in a dose-dependent manner compared to C CM (FIG. 6A). To test if Wnt3a had any effect on ALP activity induced by osteoinductive compounds, M2 cells were treated with 1.25 μM SS, 200 ng/ml Shh, or 50 ng/ml BMP-2, alone or in combination with a 1.25 dilution of Wnt3a CM. Wnt3a CM significantly inhibited both SS- and Shh-induced ALP activity (FIG. 6B). However, Wnt3a CM did not significantly inhibit BMP-2-induced ALP activity (FIG. 6B).

Oxysterol-Induced Osteogenesis is Mediated Through the PI3-Kinase/β-Catenin Pathway

To further elucidate the signaling mechanism(s) by which oxysterols regulate osteoblastic differentiation of M2 cells, we tested the effects of the PI3-kinase pathway inhibitors, LY 294002 (LY) and wortmannin (Wm) on oxysterol-induced markers of osteogenic differentiation. Pre-treatment of M2 cells with either LY or Wm significantly inhibited oxysterol-induced ALP activity in a dose-dependent manner (FIG. 7A). Similarly, Q-RT-PCR analysis showed that pre-treatment with 5 μM of either LY or Wm significantly inhibited SS-induced OCN mRNA expression after 8 days in M2 cells (FIG. 7B). A 3H-Ca incorporation assay showed that LY and Wm significantly inhibited oxysterol-induced mineralization after 14 days of treatment (FIG. 7C). Similar to their inhibitory effect on oxysterol-induced ALP activity, LY and Wm also inhibited Shh-induced ALP activity in M2 cells (FIG. 7D). We examined the effects of LY and Wm on Nkd2 and Wif-1 mRNA expression in M2 cells and found that both LY and Wm caused partial yet significant inhibition of oxysterol-induced Nkd2 and Wif-1 mRNA expression (FIGS. 7E and 7F).

We have demonstrated the role of a Wnt-related signaling pathway in oxysterol-induced osteogenic differentiation of MSC. The Wnt signaling pathway plays a role in regulating the proliferation and differentiation of osteoblasts during bone formation. Hedgehog and Wnt signaling appear to cooperate in the development of osteoblasts in vivo (20-22, 30). Our results showed that some, but not all markers of osteogenic differentiation are blocked by Dkk-1. The inhibition by Dkk-1 of oxysterol-induced ALP activity and mineralization but not of OCN expression or Runx2 DNA binding activity is consistent with the observation that oxysterol-induced osteogenic differentiation of MSC is mediated by distinct mechanisms that regulate the different aspects of this process in MSC (14). Dkk-1-inhibitable effects of oxysterols do not appear to be β-catenin dependent, because the cytosolic levels of this protein were not affected upon treatment of MSC with oxysterols, and there was no apparent induction of TCF/LeF transcriptional activity in oxysterol-treated cells. These results are consistent with other reports that demonstrate the antagonistic effect of Dkk-1 on various biological effects independent of β-catenin. Lee et al. reported that Dkk-1 antagonized Wnt signaling in human mesothelioma cells deficient in β-catenin (29), and Peng et al. showed that Dkk-1 induced apoptosis in human placental choriocarcinoma cells occurred independent of β-catenin (28). However, because there were relatively high baseline cytosolic and nuclear levels of β-catenin in M2 cells under our experimental conditions, current findings do not rule out the potential cooperative interaction between β-catenin-dependent signaling and oxysterol-induced hedgehog pathway activity. Because β-catenin/TCF/LeF dependent and independent signaling by Wnts are classically referred to as canonical and non-canonical Wnt signaling, respectively, it appears that oxysterol-induced osteogenic effects in MSC best associate with the latter phenomenon. Dkk-1 also partially inhibited Shh- and BMP2-induced ALP activity in M2 cells, but its inhibitory effects were less potent on BMP2-induced ALP activity than that induced by oxysterols or Shh. This difference may be in part due to a higher activation of Wnt signaling by BMP2 and greater reliance of BMP2 on Wnt signaling in inducing osteogenic differentiation (53, 54), requiring greater concentration of Dkk-1 to inhibit this process. In contrast, oxysterols and Shh appear to induce osteogenic differentiation by hedgehog signaling as well as a Wnt signaling-related mechanism(s). We found no evidence of hedgehog signaling being induced by BMP2 in M2 cells as evidenced by the absence of Gli-1 and Pclh expression in response to BMP2. These results are consistent with previous reports that Dkk-1 inhibits the osteogenic effects of both Shh and BMP2 (30, 54), although it is not clear whether such reported inhibitory effects of Dkk-1 are solely due to inhibition of β-catenin dependent mechanisms or also interference with β-catenin independent events.

Our present studies demonstrated that Wnt signaling target genes are selectively regulated by oxysterols and Shh through distinct mechanisms. Axin was neither induced by oxysterols nor by Shh, and Cyclin D1 was only minimally induced at 8 hours but not at 48 hours. In contrast, Nkd2 was only induced by oxysterols, and not by Shh, whereas Wif-1 was induced by both oxysterols and Shh. Differential regulation of Nkd2 expression by oxysterols and Shh is a noteworthy difference between responses induced by these osteogenic molecules. These findings, in addition to the ability of cycloamine to completely block oxysterol-induced Wif-1, but not Nkd2, and the ability of Dkk-1 to completely inhibit oxysterol-induced Nkd2, and only minimally Wif-1, suggest that the effect of oxysterols on these Wnt target genes is predominantly through either Wnt- or hedgehog-dependent signaling. Given these findings, and the fact that Dkk-1 did not affect hedgehog pathway activation by oxysterols, the oxysterol-induced biological responses in MSC may be mediated through activation of two separate pathways: 1) the hedgehog signaling pathway, and 2) the non-canonical Wnt signaling pathway with overlapping as well as distinct effects (FIG. 8). That is, oxysterols activate two distinct signaling pathways: 1) the hedgehog signaling pathway, and 2) a Dkk-1-inhibitable & β-catenin/TCF/LeF independent pathway. Activation of these pathways mediate osteogenic differentiation of MSC and cooperatively or distinctly regulate the markers and genes associated with osteogenic differentiation and Wnt signaling including alkaline phosphatase (ALP) activity, osteocalcin (OCN) mRNA expression, Wif-1 and Nkd2 expression, and matrix mineralization.

PI3-kinase inhibitors LY and Wm were able to partially or completely inhibit all the above biological responses, including those that appear to be mediated through hedgehog signaling, as well as those mediated through Dkk-1-inhibitable signaling. LY and Wm did not inhibit oxysterol-induced hedgehog pathway activation, suggesting that PI3-kinase acts downstream of this pathway. As a measure of PI3-kinase activation by oxysterols, we examined whether oxysterols induced phosphorylation of Akt by Western bloting. Despite the consistent ability of LY and Wm to inhibit oxysterol-mediated responses, decreased levels of phospho-Akt normalized to total Akt in oxysterol-treated M2 cells were not substantially induced after 10 min, 30 min, 4 hours, 8 hours, 24 hours, and 48 hours of treatments. There were significant baseline levels of phospho-Akt in M2 cells at all time points examined. However, only in 2 out of more than 8 experiments was a modest 1.5 fold increase in phospho-Akt levels observed, and only after 48 hours of treatment
with oxyesters. Rather than PI3-kinase being activated by oxyesters, the basal activity of PI3-kinase may work cooperatively with oxyesters and Shh in inducing osteogenic differentiation of M2 cells. Cooperative and/or synergistic interactions between PI3-kinase and both hedgehog and Wnt signaling have been reported. Riobo et al. reported that PI3-kinase and Akt are essential for Shh signaling during neurogenic and chondrogenic differentiation and Gli activation in progenitor cells, and that their activation by insulin-like growth factor 1 significantly enhanced Shh-induced signaling (41). In their studies, Shh itself caused only a modest activation of PI3-kinase/Akt, but the baseline level of activity may have also contributed to hedgehog signaling since LY clearly reduced the baseline levels of phospho-Akt in their experimental system. Similarly, PI3-kinase/Akt signaling was shown to mediate morphological and migratory responses of endothelial cells to hedgehog signaling (43), and PI3-kinase and hedgehog signaling were found to converge on Nmyc (a gene that is a target of hedgehog signaling in neural cells) to regulate cell cycle progression in neuroprogenitor cells (42). Furthermore, it was reported that PI3-kinase/Akt pathway mediated Wnt3a-induced proliferation of NIH3T3 cells (55), and prevention of apoptosis by Wnt proteins was in part mediated through PI3-kinase/Akt signaling, irrespective of their ability to stimulate canonical Wnt signaling (35). Wnt5a and its receptor Ror2 in Xenopus were reported to mediate gene expression in part through PI3-kinase and independently of β-catenin/Tcf/Lef (55). The role of PI3-kinase in Runx2-mediated osteogenic and chondrogenic differentiation was demonstrated in progenitor cells where inhibition by LY or a dominant-negative-Akt inhibited Runx2-dependent transcription and expression of osteogenic and chondrogenic differentiation markers (36). Our findings support the concept of cooperative interactions between hedgehog, Wnt, and PI3-kinase signaling, for example, with respect to oxyester-induced osteogenic differentiation of MSC (FIG. 8). We found that Wnt3a CM, a classic member of the Wnt family of proteins associated with the canonical Wnt signaling (57), inhibited spontaneous as well as oxyester- and Shh-induced ALP activity in MSC. This is consistent with reports by Boland et al. that Wnt3a suppressed osteogenic differentiation while promoting proliferation of human mesenchymal stem cells (57). It has been suggested that canonical Wnt signaling regulates the maintenance and proliferation of progenitor cells, which may need to be suppressed in order for these cells to undergo terminal osteogenic differentiation that may be induced by a mechanism in part dependent on non-canonical Wnt signaling (22). In support of this hypothesis, overexpression of Wnt5a as well as upregulation of Wnt11, both members of the non-canonical Wnt family, promote and enhance the osteogenic differentiation process in osteoprogenitor cells (57). In preliminary studies we found a two-fold increase in mRNA expression of Wnt5a, but not Wnt3a or Wnt10b, in oxyester-treated M2 cells after 48 hours of treatment. Both Nkd2 and Wif-1 are antagonists of Wnt signaling, and their induction by osteogenic oxyesters supports their role in promoting the terminal osteogenic differentiation of progenitor cells through inhibition of canonical Wnt signaling and proliferative activity (57). However, the role of Wnt signaling in regulation of MSC is likely to be more complex, because other investigators have reported that canonical Wnt/β-catenin signaling may in fact play a pro-differentiation role when applied to a variety of osteoprogenitor cells in vitro (58-61). Such variations in the reported observations may be due to differences in experimental models used by different investigators, as well as differences in commitment stage of various progenitor cells to the osteogenic lineage. Despite these differences, in vitro and in vivo data clearly demonstrate the positive role of Wnt signaling in the development and maintenance of osteoblasts and bone, either through positive regulation of proliferation and maintenance of an osteoprogenitor pool, and/or through pro-osteogenic differentiation effects on these cells. Rodda and McMahon demonstrated distinct roles for hedgehog and Wnt signaling in specification, differentiation, and maintenance of osteoblast progenitors (62). That specific oxyesters mediate their biological effects in part through regulation of Wnt signaling, in addition to hedgehog signaling, supports their role in osteoblast biology.

EXAMPLES

Materials

M2-10B4 cells were purchased from American Type Culture Collection (Rockville, Md.). Oxyesters, β-glycerophosphate (β-GP), and ascorbate were obtained from Sigma-Aldrich, Co. (St. Louis, Mo.). RPMI 1640 was obtained from Irvine Scientific (Santa Ana, Calif.), fetal bovine serum (14138) was obtained from HyClone (Logan, Utah), recombinant mouse Shh N-terminal peptide, recombinant human BMP2, and recombinant mouse Dickkopf related protein 1 (Dkk-1) were obtained from R&D Systems, Inc. (Minneapolis, Minn.), and cyclosporine, LY 294002, and wortmannin were obtained from EMD Biosciences, Inc. (La Jolla, Calif.). Wnt3a conditioned medium (Wnt3a CM) and empty vector conditioned medium (C CM) were generous gifts from Dr. Peter Tontonoz (UCLA, Los Angeles, Calif.).

Cell Cultures

M2-10B4 cells were maintained in RPMI 1640 with 10% heat-inactivated FBS, supplemented with 1 mM sodium pyruvate, 100 U/ml penicillin and 100 U/ml streptomycin as previously described (13). Treatments were performed in osteogenic differentiation medium containing 5% FBS, 50 μg/ml ascorbate, and 3 mM β-GP.

Example 1

General Alkaline Phosphatase (ALP) Activity Assay

Colorimetric alkaline phosphatase (ALP) activity assay on whole cell extracts was performed as previously described (13).

Example 2

General 45Ca Incorporation Assay

45Ca incorporation assay as a measure of matrix mineralization in cell monolayers was performed as previously described (45).

Example 3

General Quantitative RT-PCR (Q-RT-PCR) Procedure

Total RNA was extracted with the RNA isolation kit from Stratagene (La Jolla, Calif.) according to the manufacturer’s instructions. RNA was DNase-treated using the DNA-free kit from Ambion, Inc. (Austin, Tex.). 3 μg of RNA was reverse-transcribed using reverse transcriptase from Stratagene (La Jolla, Calif.) to make single stranded cDNA. The cDNAs were mixed with Qi SYBR Green Supermix from...
Bio-Rad Laboratories (Hercules, Calif.) for quantitative RT-PCR using a Bio-Rad I-cycler IQ quantitative thermocycler. All PCR samples were prepared in triplicate or quadruplicate. Each sample was added to duplicate wells of a 96-well plate. After 40 cycles of PCR, melt curves were analyzed in order to ensure primer specificity, and the identity of all PCR products were verified by sequencing and comparing with the complete mRNA sequence obtained from PubMed’s GenBank. Fold changes in gene expression were calculated using the ΔΔCt method (14). All primers were designed using the Beacon Designer software from Bio-Rad Laboratories (Hercules, Calif.). Primers used are as follows: OCN (5'-TCTCTCTCGACCTCACAGATGCC-3' (SEQ ID NO: 1) and 5'-TTACCTAATGGCCCTCAGTGTG-3' (SEQ ID NO: 2)), Axin2 (5'-GAAGGCGAGAGCCACACAAGA-3' (SEQ ID NO: 3) and 5'-CTGGGGCCAGACTG-CAAGAC-3' (SEQ ID NO: 4)), Cyclin D1 (5'-GACACCTACCTTCCAGACAG-3' (SEQ ID NO: 5) and 5'-TACAGACACTTCCAGACATCC-3' (SEQ ID NO: 6)), NKD2 (5'-GAAAGACACCGCGAAGAACTG-3' (SEQ ID NO: 7) and 5'-GGGAGGAGTATCTGACAGGAG-3' (SEQ ID NO: 8)), WIT-1 (5'-GAAGTGAATGCGGCGGAGAAG-3' (SEQ ID NO: 9) and 5'-CTGGCTCTCATACTCTTTATGC-3' (SEQ ID NO: 10)), and GAPDH (5'-ATGTGCACAGATGCATCTTGC-3' (SEQ ID NO: 11) and 5'-ATGGACTGTGGTCATGAGCC-3' (SEQ ID NO: 12)).

Example 4

General Transient Transfection and Reporter Assay

M-210B4 cells at 70% confluence were transfected for 24 hours using FuGENE 6 Transfection Reagent (Roche Applied Science, Indianapolis, Ind.) according to manufacturer's instructions. The wild-type and mutant TCF/LEF binding site driven luciferase constructs (TBE4-luc and TBE4-luc-mut, respectively) were generous gifts from Dr. Bartuch Frenkel (University of Southern California, Los Angeles, Calif.), and the Cyclin D1 promoter element-driven luciferase construct (Cyclin D1-luc) was a generous gift from Dr. Fanxin Long (Washington University, St. Louis, Mo.). Firefly luciferase activities were normalized to Renilla luciferase activity and pEGFP-N1 was used to evaluate transfection efficiency. Cells were then transfected for 24, 48, or 72 hours with test agents before measuring luciferase activity using the Dual-Luciferase Reporter 1000 Assay System (Promega, Madison, Wis.) according to the manufacturer’s instructions.

Example 5

General Cytosolic Protein Extraction and Total Cell Lysate Preparation

M-210B4 cells were dounce homogenized 25 times in HLBP Buffer [10 mM HEPES/KOH, pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM DTT, 1:100 protease inhibitor cocktail (EMD Biosciences, Inc., La Jolla, Calif.), 1:100 phosphatase inhibitor cocktail 1 and 2 (Sigma, St. Louis, Mo.), then spun down at 2,500 rpm for 5 minutes at 4°C. The supernatant was collected and spun down at 19,000 rpm for 30 minutes at 4°C. The supernatant after this spin was collected and saved as the cytosolic protein extract. For preparation of total cell lysates, M-210B4 cells were incubated on ice for 15 minutes in lysis buffer (50 mM NaCl, 5 mM EDTA, 80 mM EGTA, 10 mM HEPES/KOH, pH 7.9, 0.1% Triton X-100, and 1:100 protease inhibitorcocktail (EMD Biosciences, Inc., La Jolla, Calif.). For phospho-lated proteins 0.1 mM sodium vanadate (Na3VO4) was also included in the lysis buffer. Each sample was then sonicated and spun down at 12,000 rpm for 5 minutes at 4°C. The supernatant after this spin was collected and saved as the total cell lysate.

Example 6

General Western Blot Analysis

Protein concentrations were determined using the Bio-Rad protein assay (Hercules, Calif.), and SDS-PAGE was performed as previously described (46). Briefly, cytosolic extracts or total cell lysates (30 μg) were separated on a 10% Tris-HCl gel from Bio-Rad laboratories (Hercules, Calif.) and transferred overnight onto a nitrocellulose membrane from Amersham Biosciences (Piscataway, N.J.). Blocking was performed with 5% dry skim milk (Beeton, Dickinson and Company, Sparks, Md.) in Tris-buffer saline containing 0.1% Tween-20 (TBS-T) for 2 hours at room temperature. Blots were then incubated with the monoclonal antibody against phospho(Ser473)-Akt, or the polyclonal antibodies against Akt, β-catenin or β-actin (Cell Signaling Technology, Danvers, Mass.), following the instructions of the manufacturer. Binding of the primary antibody was detected by a secondary antibody labeled with horse-radish peroxidase (Santa Cruz Biotechnology, Inc., Santa Cruz, Calif.). The blots were developed using enhanced chemiluminescence detection reagents (Perkin Elmer, Boston, Mass.).

Statistical Analysis

Computer-assisted statistical analyses were performed using the StatView 4.5 program. All p values were calculated using ANOVA and Fisher’s projected least significant difference (PLSD) significant test. A value of p < 0.05 was considered significant.

Example 7

The LRPS/6 Inhibitor, Dickkopf-1 (Dkk-1), Inhibits Oxyosteryl-Induced Osteogenic Differentiation in Marrow Stromal Cells

Alkaline phosphatase (ALP) activity assay (see Example above) was performed in M2 cells pre-treated with 1 or 2 μg/ml Dkk-1 or vehicle for 2 hours followed by treatment for 3 days with control vehicle or 2.5 μM of the oxysterol combination, SS (A), 200 ng/ml Shh (B), or 50 ng/ml BMP-2 (C) (see FIGS. 2A-2C). Results from a representative experiment are reported as the mean of quadruplicate determinations±S.D. and normalized to protein concentrations (p<0.01 for Control versus SS, Shh and BMP-2 and SS and Shh versus SS and Shh plus Dkk-1 at both concentrations; p<0.02 for BMP-2 versus BMP-2 plus 2 μg/ml Dkk-1).

Ca incorporation assay (see Example above) was used to measure mineralization in M2 cells pre-treated with 1 μg/ml Dkk-1 or vehicle for 2 hours, and then treated with control vehicle or 2.5 μM SS 12 days (See FIG. 2D). Data from a representative experiment are reported as the mean of quadruplicate determinations±S.D. and normalized to protein concentrations (p<0.01 for Control versus SS and SS versus SS plus Dkk-1).

M2 cells were pre-treated with vehicle or 1 μg/ml Dkk-1 for 2 hours followed by treatment with control vehicle or 5 μM SS for 6 days. RNA was isolated and analyzed by Q-RT-PCR for OCN expression (See FIG. 2E). Data from a represen-
Example 8

Effect of Osteogenic Oxysterols on TCF/Lef Transcriptional Activity in Marrow Stromal Cells

M2 cells were transfected with a luciferase reporter driven by 4 wild-type or mutant TCF/Lef DNA binding sites (TBE4-luc and TBE4-luc-mut, respectively) and analyzed for their response to 5 μM SS, 200 ng/ml Shh, 40 mM LiCl, or control vehicle after 24 h of treatment (see Fig. 3A). Data from a representative experiment are reported as the mean of triplicate samples±S.D. and normalized to Renilla luciferase activity (p<0.001 for Control versus LiCl with TBE4-luc expression vector).

Example 9

Osteogenic Oxysterols Differentially Regulate Wnt Target Gene Expression in Marrow Stromal Cells

M2 cells were treated with 5 μM SS, 200 ng/ml Shh, 40 mM LiCl, or control vehicle for 8 or 48 h. RNA was isolated and analyzed by Q-RT-PCR for Axing expression (See Figs. 4A and 4B). Data from a representative experiment are reported as the mean of triplicate determinations±S.D. and normalized to GAPDH expression (p<0.02 for Control versus LiCl at 8 h and 48 h, and for Control versus SS at 48 h).

Example 10

Osteogenic Oxysterols Differentially Regulate Wnt Target Gene Expression in Marrow Stromal Cells

M2 cells were pre-treated for 2 h with vehicle or cyclospamine (Cyc) at the concentrations indicated. Next, cells were treated with 5 μM SS or control vehicle for 48 h. RNA was isolated and analyzed for Nkd2 (A) and WIF-1 (B) expression by Q-RT-PCR (See Figs. 5A and 5B). Data from a representative experiment are reported as the mean of triplicate determinations±S.D. and normalized to GAPDH expression (p<0.001 for Control versus SS for both, Nkd2 and Wif-1 expression, and for SS versus SS+Ncy at both, 2 and 4 μM, for Wif-1 expression).

M2 cells were pre-treated for 2 h with Dkk-1 or vehicle. Next, cells were treated with 5 μM SS or control vehicle for 48 h. RNA was isolated and analyzed for Nkd2 (C), Wif-1 (D), and Pch2 (E) expression (See Figs. 5C-5E). Data from a representative experiment are reported as the mean of triplicate determinations±S.D. and normalized to GAPDH expression (p<0.01 for Control versus SS for Nkd2, Wif-1, and Pch2 expression; p<0.001 for SS versus SS plus Dkk-1 for Nkd2 expression; p<0.05 for SS versus SS plus Dkk-1 for Wif-1 expression).

Example 11

Wnt3a Conditioned Medium Inhibits Oxysterol-Induced Alkaline Phosphatase Activity in Marrow Stromal Cells

A cell-associated alkaline phosphatase activity (ALP) assay is used as a screen to identify potential osteoinductive oxysterols. The protocol is a modification of alkaline phosphatase assay kit from Sigma. Cells are cultured in 24-well tissue culture plates. After treatments with test agents, cells are rinsed twice with PBS and scraped into 200 ml of lysis buffer (0.2% NP-40 in 1 mM MgCl2) and sonicated for 10 seconds. Next, 1 ml of reaction mixture is added to each well. Reaction mixture is 221 alkaline buffer (Sigma); stock substrate solution (1:1). Stock substrate solution is prepared by dissolving 40 mg of Sigma 104 phosphate substrate in 10 ml of ddH2O. After addition of reaction mixture to lysed cells, incubation is performed for 30 minutes at 37 C. The yellow color is indicative of alkaline phosphatase activity. The reaction is stopped by the addition of 12 ml of 1N NaOH to each well, and absorbance is determined at 405 nm. Alkaline phosphatase activity is calculated using p-nitrophenol as a standard, according to Sigma kit’s instructions. Results are normalized to total protein in each well determined using the Bio-Rad protein assay solution (Bio-Rad Laboratories).

An ALP activity assay was performed in M2 cells treated for 6 days in osteogenic medium with various dilutions of Wnt3a conditioned medium (Wnt3a CM) or control conditioned medium (C CM) (See Fig. 6A). Results from a representative experiment are reported as the mean of triplicate determinations±S.D. and normalized to protein concentrations (p<0.05 for all C CM versus Wnt3a CM (1.25) and (1.50)).

An ALP activity assay in M2 cells treated for 5 days with 1.25 μM SS, 200 ng/ml Shh, 50 ng/ml BMP-2, or control vehicle, in combination with either C CM or Wnt3a CM at a 1:25 dilution was performed (See Fig. 6B). Results from a representative experiment are reported as the mean of quadruplicate determinations±S.D. and normalized to protein concentrations (p<0.02 for Control versus SS, Shh and BMP-2, and for SS and Shh versus SS and Shh plus Wnt3a CM).

Example 12

Oxysterol-Induced Osteogenesis is Mediated by the P38-Kinase Pathway in Marrow Stromal Cells

ALP activity assay in M2 cells pre-treated with various doses of the P38-kinase inhibitors, LY 294002 (LY) or wortmannin (Wm) or vehicle for 2 h followed by treatment
for 3 days with 2.5 µM SS control vehicle was performed (See FIG. 7A). Results from a representative experiment are reported as the mean of quadruplicate determinations±S.D. and normalized to protein concentrations (p<0.001 for Control versus SS, and for SS versus SS plus LY or Wm at all concentrations).

M2 cells were pre-treated with 5 µM LY, 2.5 µM Wm, or vehicle for 2 h followed by treatment with 2.5 µM SS control vehicle for 6 days. RNA was analyzed for OCN expression by Q-RT-PCR and normalized to GAPDH (p<0.01 for Control versus SS and for SS versus SS+LY and SS+Wm) (See FIG. 7B).

45Ca incorporation assay was used to measure mineralization in M2 cells pre-treated with various doses of LY, 1 µM Wm, or vehicle for 2 h, and then treated with 5 µM SS or control vehicle for 14 days (See FIG. 7C). Data from a representative experiment are reported as the mean of quadruplicate determinations±S.D. and normalized to protein concentrations (p<0.001 for Control versus SS, and for SS versus SS+LY and SS+Wm at all concentrations).

M2 cells were pretreated with 5 µM LY, 1 µM Wm, or vehicle for 2 h followed by treatment with 200 ng/ml Shh or control vehicle for 3 days. ALP activity assay was performed and results from a representative experiment are reported as the mean of quadruplicate determinations±S.D. and normalized to protein concentrations (p<0.001 for Control versus Shh and for Shh versus Shh+LY and Shh+Wm) (See FIG. 7D).

M2 cells were pre-treated for 2 h with 5 µM LY, 2.5 µM Wm, or vehicle followed by treatment with 5 µM SS or control vehicle for 48 h. RNA was isolated and analyzed for Nkd2 (FIG. 7E) and Wif-1 (FIG. 7F) expression. Data from a representative experiment are reported as the mean of triplicate determinations±S.D. and normalized to GAPDH expression (p<0.01 for Control versus SS, and for SS versus SS plus LY and Wm for both Nkd2 and WIF-1 expression).

### Example 14

**Effect of Oxysterols on Alkaline Phosphatase Activity in M2-10B4 Marrow Stromal Cells**

M2-10B4 marrow stromal cells were treated with oxysterols at various doses for 3 days after which they were collected and analyzed by colorimetric assay for alkaline phosphatase activity (a marker of osteoblastic differentiation) (Table 2); the alkaline phosphatase assay described above was used. Results from a representative experiment are shown as the fold induction in alkaline phosphatase activity compared to control untreated cells.

### Example 15

**Effect of Various Oxysterol Molecules on Alkaline Phosphatase Activity in Marrow Stromal Cells**

M2-10B4 bone marrow stromal cells were treated in culture with control vehicle (C) or various oxysterol (Oxy) molecules as indicated at either 1.25 (1) or 2.5 (2) µM concentrations. After 3 days of treatment, alkaline phosphatase activity as a measure of early osteogenic differentiation of cells was measured in whole cell lysates (See FIG. 9 and Table 3); the alkaline phosphatase assay described above was used. Results are reported as the mean of quadruplicate determinations±S.D. (p<0.001 for C vs. all Oxy conditions except for Oxy51(1) and Oxy53(1) where p<0.05 and therefore not significant, and p<0.05 for C vs. Oxy52(1). Table 3 reports results as fold induction over control untreated cells.
Example 16

Effect of Various Oxyesters on Osteocalcin mRNA Expression in Bone Marrow Stromal Cells

M2-10B4 cells were treated with control vehicle (C) or various doses (μM) of oxyesters as indicated. After 6 days of treatments, RNA was extracted from cells and analyzed by Q-RT-PCR for osteocalcin and GAPDH expression (See FIG. 11). Data from a representative experiment are reported as the mean of triplicate determinations±SD normalized to GAPDH.

Example 17

Effect of Various Oxyesters on Adipogenesis of Bone Marrow Stromal Cells

M2-10B4 cells were treated with control vehicle (C) or the inducer of adipogenesis, Troglitazone (Tro, 10 μM), alone or in combination with various oxyesters (5 μM). After 10 days of treatments, cells were stained with Oil red O to detect adipocytes. Adipocytes were counted in triplicate wells per condition, 5 fields per well (See FIG. 12). Data from a representative experiment are reported as the mean of triplicate determinations±SD.

For example, M2-10B4 cells were treated with control vehicle (C) or the inducer of adipogenesis, Troglitazone (Tro, 10 μM), alone or in combination with Oxy34 (5 μM). After 10 days of treatments, cells were stained with Oil red O to detect adipocytes. Adipocytes were counted in triplicate wells per condition, 5 fields per well. Data from a representative experiment are reported as the mean of triplicate determinations±SD (See FIG. 13).

Example 18

Effect of Oxy49 and Shh on Gli Induced Reporter Activity

M2-10B4 bone marrow stromal cells were transfected with an 8XGli luciferase reporter or the empty vector (pGL3b). Cells were subsequently treated with control vehicle, 5 μM Oxy49, or 400 ng/ml recombinant human sonic hedgehog (Shh) as positive control. After 48 hours of treatments, reporter luciferase activity was measured and normalized to Renilla luciferase activity (See FIG. 14). Data from a representative experiment are reported as the mean of quadruplicate determinations±SD.

Example 19

Effect of Oxy34 and Shh on Gli Induced Reporter Activity

M2-10B4 bone marrow stromal cells were transfected with an 8XGli luciferase reporter or the empty vector (pGL3b). Cells were subsequently treated with control vehicle, 5 μM Oxy34, or 400 ng/ml recombinant human sonic hedgehog (Shh) as positive control. After 48 hours of treatments, reporter luciferase activity was measured and normalized to Renilla luciferase activity (See FIG. 15). Data from a representative experiment are reported as the mean of quadruplicate determinations±SD.

Example 20

Effect of Various Oxyesters on Gli 1 and Patched mRNA Expression in Bone Marrow Stromal Cells

M2-10B4 cells were treated with control vehicle (C) or various oxyesters (5 μM) as indicated. After 48 hours of treatments, mRNA was extracted from cells and analyzed by Q-RT-PCR for expression of hedgehog target genes Gli 1 and Patched (See FIGS. 16A and 16B). Data from a representative experiment are reported as the mean of triplicate determinations±SD normalized to GAPDH.

Example 21

Effect of Various Oxyesters on Bone Sialoprotein mRNA Expression in Bone Marrow Stromal Cells

M2-10B4 cells were treated with control vehicle (C) or various doses (μM) of oxyesters (Oxy34 or Oxy49) as indicated. SS, refers to 5 μM each of 20S-hydroxycholesterol+22S-hydroxycholesterol used as a positive control. After 6 days of treatments, mRNA was extracted from cells and analyzed by Q-RT-PCR for expression of hoxbap and GAPDH expression (See FIG. 17). Data from a representative experiment are reported as the mean of triplicate determinations±SD normalized to GAPDH.

Example 22

Effect of Various Oxyester Molecules on Bone Sialoprotein (BSP) Expression in Bone Marrow Stromal Cells [Oxy50-Oxy54]

M2-10B4 bone marrow stromal cells were treated in culture with control vehicle (C) or various oxyester (Oxy) molecules as indicated at 2.5 μM concentration. After 48 hours of treatment. RNA was isolated and analyzed for BSP expression by Q-RT-PCR as a measure of osteogenic differentiation (See FIG. 10). Results are reported as the mean of triplicate determinations±SD (p<0.001 for C vs. Oxy49 and Oxy50)

Example 23

Effect of Various Oxyesters on Mineralization of Bone Marrow Stromal Cells

M2-10B4 cells were treated for 14 days with control vehicle (C) or various concentrations (μM) of oxyesters as indicated. SS refers to 20S-hydroxycholesterol+22S-hydroxycholesterol in combination. After 12 days with refeeding every 5th day, 4Ca was added and on day 14, 4Ca incorporation was measured (See FIG. 18). Data from a representative experiment are reported as the mean of quadruplicate determinations±SD. The data indicate that administration of oxyester compound Oxy34 or Oxy49 or the oxyester combination SS increased mineralization. The oxyesters Oxy34 and Oxy49 induce BSP expression; Oxy34 and Oxy49 have a hydroxyl group substituted onto the 6-carbon of the B-ring. A hydroxyl group substituent on the number 6 carbon of the B-ring was observed to result in increased osteoinductive potential of the Oxy molecules. Treatment of 20S does not have a hydroxyl group substituted onto the 6-carbon of the B-ring.
Hedgehog Signaling:

All of the oxyesters presented in FIG. 1 activated the hedgehog signaling pathway as assessed by at least one of the following methodologies:
1. Luciferase reporter activity using a reporter construct with 8X-Gli binding sites
2. Q-RT-PCR analysis of the induction of hedgehog pathway target gene expression Gli 1 and Patched
3. Inhibition of the osteoinductive effects of the oxyesters by hedgehog pathway inhibitor, cyclopamine

Expression of Bone Sialoprotein (BSP):

We considered the ability of oxyesters to induce the expression of BSP in M2-10B4 marrow stromal cells. Oxyesters that induce BSP expression, such as Oxy34 and Oxy49, can be potent inducers of osteoblastic differentiation and mineralization in M2-10B4 cell cultures. Oxyesters that induce other markers of osteoblastic differentiation including 1) alkaline phosphatase activity and 2) osteocalcin mRNA expression, but not BSP expression, induce mineralization at higher doses than those oxyesters which also induce BSP expression, for example Oxy34 and Oxy49. Oxyesters that induce 1) alkaline phosphatase activity, 2) osteocalcin mRNA expression, and 3) BSP expression can be optimal in inducing bone growth. Such osteogenesis or bone mineral formation can be assessed by 45Ca incorporation assay in cultures of M2-10B4 cells.

Based on our structure-activity relationship studies discussed herein, it appears that the OH groups on C3 and C20 of an oxyester are important for the induction of osteogenesis as measured by the induction of various markers of osteogenic differentiation including alkaline phosphatase activity and osteocalcin mRNA expression. The induction of bone sialoprotein (BSP) mRNA expression may be a prerequisite for the maximal potency of oxyesters, such as the Oxy molecules considered herein, to induce mineralization in cultures of M2-10B4 marrow stromal cells when used at nanomolar to low micromolar concentrations. Therefore, induction of BSP expression may be important for the osteoinductive property of oxyesters. The osteoinductive potential of oxyesters appears to increase when a double bond is added between C25 and C27 of 20(S)-hydroxycholesterol. Therefore, we envision all molecules and their variations that contain the basic structure of 20(S)-hydroxycholesterol with an added double bond at the end of the fatty acid side chain, for example, between C25 and C27, and a hydroxyl group on C6 of the B ring, as being useful for inducing osteogenesis, bone mineralization, and other biochemical phenomena. An example is Oxy49 shown below:

Synthesis Example 1

Oxy22

1·(3S,8S,9S,10R,13S,14S,17S)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-Tetradecahyro-3-[(1,1-dimethyl-ethyl)dimethyl(silyloxy)-10,13-dimethyl-1H-cyclopenta[a]phenanthren-17-yl]ethaneone (1)

To a stirred solution of pregnenolone (5.0 g, 15.8 mmol) in anhydrous dimethylformamide (DMF, 180 mL) was added imidazole (2.7 g, 39.7 mmol). The reaction was allowed to stir for 20 min followed by slow addition of tert-butyldimethylsilyl chloride (5.6 g, 23.9 mmol). After stirring for 12 h at ambient temperature, the reaction mixture was poured over ice. The precipitates were collected and dissolved in diethyl ether. The organic phases were washed with brine, dried over Na2SO4 and evaporated in vacuo to yield compound 1 (6.7 g, 15.6 mmol, 98%) as a white powder, which was used without further purification. The spectroscopic data were identical to those reported in the literature (66).

(3S,8S,9S,10R,13S,14S,17R)-17-(2,3,4,7,8,9,10,11,12,13,14,15,16,17-Tetradecahydro-3-[(S)-2-hydroxy-5-phenylpent-2-yl])10,13-dimethyl-1H-cyclopenta[a]phenanthren-3-ol (2, [Oxy22])

To a stirred suspension of magnesium turnings (106.7 mg, 4.4 mmol) in anhydrous diethyl ether (3.5 mL) was added (3-bromopropyl)benzene (199.0 mg, 1.22 mmol). After stirring under reflux for 2 h, the initially produced Grignard reagent was cannulated into a solution of the protected pregnenolone (300 mg, 0.70 mmol) in anhydrous tetrahydrofuran (THF, 20 mL) and the solution was refluxed for an additional 2 h. The mixture was cooled in an ice bath and treated with satd. NH4Cl. The solution was filtered through Celite and the precipitate washed three times with diethyl ether. The filtrate was extracted twice with diethyl ether. The organic layers were combined and washed with satd. NaCl, dried over Na2SO4 and evaporated in vacuo to afford a residue, which was subjected to flash column chromatography on silica gel. Elution with hexane-diethyl ether (2:1 v/v) afforded the alcohol. The silyl ether was then treated with a 1.0 M solution of tetrabutylammonium fluoride (TBAF) in THF (1.0 mL, 1.0 mmol), and the mixture was allowed to stir at 20° C. After stirring for 12 h, the reaction was treated with water and extracted three times with diethyl ether and the organic layer was washed with satd. NaCl. The organic phases were collected, dried over Na2SO4 and concentrated in vacuo to give an oil. Flash column chromatography of this oil (silica gel, 1:2 hexane/diethyl ether) yielded the diol 2 (170.0 mg, 56% over 2 steps) as a white powder.
**Synthesis Example 2**

**Oxy27**

\[(S)-2-(5H)(S),9S,10R,13S,14S,17S)-17-((S)-2-Hydroxy-4-phenylbutan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-11H-cyclopent[a]phenanthren-3-ol (3) ([Oxy27])**

The Grignard reagent prepared from (2-bromoethyl)benzene (958 mg, 5.17 mmol) in 10.0 mL of anhydrous diethyl ether in the presence of magnesium turnings (500 mg, 20.6 mmol) was added to pregnenolone 1 (300 mg, 0.69 mmol) under similar conditions to those described for the preparation of 2. Desilylation was carried out as above with TBAF to afford the diol 3 ([Oxy27] 200.0 mg, 69% over 2 steps) as a white powder.

**Synthesis Example 3**

**Oxy26**

\[(S)-2-(5S,9S,10R,13S,14S,17S)-3-[[1,1-Dimethylethyl(dimethylsilyloxy)]-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-11H-cyclopent[a]phenanthren-17-yl]-pent-4-yn-2-ol (4) \n
To a stirred suspension of magnesium turnings (6.0 g, 246.9 mmol) in anhydrous diethyl ether (150 mL) and mercuric chloride (700 mg, 2.6 mmol) was slowly added a solution of propargyl bromide (7.0 g, 58.8 mmol) in diethyl ether (50 mL). After stirring under reflux for 20 min, the initially produced Grignard reagent was converted into a solution of the protected pregnenolone 1 (4.5 g, 14.2 mmol) in anhydrous THF (20 mL) and the mixture was refluxed for an additional 1 h. The mixture was quenched with satd. NH4Cl in an ice bath for 30 min and extracted three times with diethyl ether. The organic layer was washed with satd. NaCl. The organic phases were collected, dried over Na2SO4 and concentrated in vacuo to afford a crude yellow solid. Flash column chromatography (silica gel, 1:10 diethyl ether/hexane v/v) yielded the propargylic alcohol 4 (3.65 g, 72%) as a white powder. The spectroscopic data was identical to that reported in the literature (67).
The silyl ether 5 (50 mg, 0.90 mmol) was dissolved in THF and treated with a 1.0 M solution of tetrabutylammonium fluoride in THF (2.0 mL, 2.0 mmol) and the mixture was allowed to stir at 20°C. After stirring for 12 h, the reaction was treated with water and extracted three times with diethyl ether and the organic layer was washed with satd. NaCl. The organic phases were collected, dried over Na2SO4 and concentrated in vacuo to give an oil. Flash column chromatography of this oil (silica gel, 13 hexane/diethyl ether v/v) yielded the diol 6 (Oxy26) (42.0 mg, 96%) as a white powder.

1H NMR (CDCl3; 400 MHz) δ: 7.19 (1H, dd, J=5.2, 1.2 Hz), 7.14 (1H, dd, J=3.6, 1.1 Hz), 6.95 (1H, dd, J=5.2, 3.6 Hz), 5.33-5.31 (1H, m), 3.52-3.44 (1H, m), 2.58 (1H, q, J=19.6 Hz), 2.19-1.49 (18H, m), 1.47 (3H, s), 1.26-1.03 (44H, m), 1.01 (3H, s). 13C NMR (CDCl3; 100 MHz) δ: 141.6, 131.3, 126.8, 126.3, 123.7, 121.1, 99.0, 89.9, 75.2, 74.5, 57.7, 56.9, 50.1, 42.8, 40.0, 37.4, 36.6, 35.2, 32.1, 32.0, 31.5, 31.4, 27.0, 23.8, 22.5, 21.1, 20.2, 19.4, 13.5

Synthesis Example 4
Oxy39

To a solution of trimethylsilylacetylene (500 mg, 5.01 mmol) in 5.0 mL of anhydrous THF, was added n-butyllithium (1.0 mL, 2.5 mmol) at 0°C. After 30 min, a solution of the pregrenone 1 (500 mg, 1.58 mmol) in THF (10 mL) was added slowly. The reaction was quenched with 1 h with satd. NH4Cl and extracted twice with diethyl ether. The organic layers were combined and washed with satd. NaCl, dried over Na2SO4 and evaporated in vacuo to afford a crude solid, which upon treatment with potassium carbonate (600 mg, 4.34 mmol) in 6.0 mL mixture of methanol/THF (5:1 v/v) yielded the crude desilylated pregrenic acid. The solvent was removed and extracted with diethyl ether. The organic phases were collected, dried over Na2SO4 and evaporated in vacuo to give a residue which was purified by column chromatography on silica gel using hexane-diethyl ether (2:1 v/v) as eluent to afford the silyl ether 7 (360 mg, 78% over two steps) as a white solid.

1H NMR (CDCl3; 400 MHz) δ: 7.20-7.13 (2H, m), 7.07-6.97 (2H, m), 5.33-5.32 (1H, m), 3.53-3.45 (1H, m), 2.66 (2H, t, J=19.6 Hz), 2.15-1.45 (18H, m), 1.39 (3H, s), 1.26-1.04 (6H, m), 1.01 (3H, s). 13C NMR

(38,88,9S,10R,13S,14S,17S)-2-((38,88,9S,10R,13S,14S,17S)-3-[(1,1-Dimethylethylidimethylsilyloxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)but-3-yn-2-ol (7)
(CDCl₃, 100 MHz) δ: 163.1, 159.9, 141.6, 130.5, 130.4, 129.6, 129.4, 127.5, 127.4, 124.0, 123.9, 121.1, 115.3, 115.1, 75.1, 72.6, 58.0, 57.0, 50.1, 44.1, 42.8, 42.7, 40.2, 37.4, 36.7, 32.1, 31.8, 31.4, 26.1, 24.0, 23.8, 22.4, 20.9, 19.4, 13.6. 19F (CDCl₃; 400 MHz) δ: -119.7

**Synthesis Example 5**

**Oxy42**

(3S,8S,9S,10R,13S,14S,17S)-17-(1S)-2-Hydroxy-5-[(S)-(2-hydroxyethyl)amino]-10,13-dimethyl-2,3,4,5,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3-ol (9, [Oxy42])

To a solution of the alkyn silyl ether 5 (40 mg, 0.72 mmol) in 2.0 mL of a mixture of dichloromethane/absolute ethanol (1:1 v/v), was added Pd/C (20% mol). The reaction was left under a hydrogen atmosphere for 12 h. The crude mixture was filtered through Celite using dichloromethane and the solvent was removed under reduced pressure. The residue was treated with a 1.0 M solution of tetrabutylammonium fluoride in THF (2.0 mL, 2.0 mmol), and the mixture was allowed to stir at 20°C. After stirring for 12 h, the reaction was treated with water and extracted three times with diethyl ether and the organic layer was washed with satd. NaCl. The organic phases were collected, dried over Na₂SO₄ and concentrated in vacuo to give an oil. Flash column chromatography of this oil (silica gel, 1:3 hexane/diethyl ether v/v) afforded the diol 9 (Oxy42) in quantitative yield as a white powder.

**Synthesis Example 6**

**Oxy40**

(3S,8S,9S,10R,13S,14S,17S)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3-(1,1-dimethyl-ethyl)dimethylsilyloxy)-17-(3S)-2-hydroxy-6-methylhept-6-en-2-yl)-10,13-dimethyl-1H-cyclopenta[a]phenanthrene (10)

The coupling reaction of the protected pregnenolone 1 (500.0 mg, 1.16 mmol) with 5-bromo-2-methyl-1-pentene (199.0 mg, 1.22 mmol) in the presence of samarium diiodide was performed as reported (69a) to afford the 20S-hydroxy steroid 10 (419.0 mg, 0.82 mmol, 71%) as a white powder. The spectroscopic data were identical to those reported in the literature (69b).

**Synthesis Example 7**

**Oxy40**

(3S,8S,9S,10R,13S,14S,17S)-3-[1,1-Dimethyl-ethyl]dimethylsilyloxy]-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl]-2-methylheptane-1,6-diol (11)

To a solution of the dienyl silyl ether 10 (30 mg, 0.055 mmol) in THF (1.0 mL) cooled to 0°C was added 0.08 mL of BH₃ (1.0 M in THF). The reaction was allowed to warm to 20°C over 3 h. A mixture of 1.2 mL of NaOH (10%) and 0.3 mL of H₂O₂ (30%) was then added at 0°C, and the mixture was allowed to warm to 20°C over 1 h (70a). The reaction mixture was extracted three times with diethyl ether. The organic phases were collected, dried over Na₂SO₄ and evaporated in vacuo to afford an oil. Flash column chromatography of this crude oil (silica gel, 1:1 hexane/diethyl ether v/v) afforded the diol 11 (12 mg, 40%) as a undefined diastereomeric mixture.

**Oxy40**

(3S,8S,9S,10R,13S,14S,17S)-3-Hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-yl]-2-methylheptane-1,6-diol (12, [Oxy40])

The dihydroxy silyl ether 11 (12 mg, 0.023 mmol) was dissolved in THF and treated with a 1.0 M solution of tetrabutylammonium fluoride in THF (0.10 mL, 0.10 mmol), and the mixture was allowed to stir at 20°C. After stirring for 12 h, the reaction was treated with water and extracted...
three times with diethyl ether and the organic layer was washed with satd. NaCl. The organic phases were collected, dried over Na₂SO₄ and concentrated in vacuo to give an oil. Flash column chromatography of this oil (silica gel, 1:3 hexane/diethyl ether v/v) yielded the triol 12 (Oxy40) (12.0 mg, 96%).

1H NMR (CDCl₃; 500 MHz) δ: 5.32-5.31 (1H, m), 3.87-3.81 (2H, m), 3.52-3.48 (1H, m), 2.35-1.43 (22H, m), 1.25-1.24 (7H, m), 1.23 (3H, s), 1.09 (3H, s), 1.0 (3H, s), 0.90 (3H, dd, J=6.7, 2.7 Hz).

Synthesis Example 7

Oxy41

(6S)-6-[(3S,6S,8R,9S,10R,13S,14S,17S)-3-[(1,1-Dimethylallyl)dimethylsiloxyl]-6-hydroxy-10,13-dimethylhexadeca-1,5,9-triene-17-yl]2-methylheptane-1,6-diol (13)

To a solution of the dienyl silyl ether 10 (100 mg, 0.19 mmol) in THF (3.0 mL) at 0°C, added 1.0 M of BH₃ in THF (2.0 mL, 2.0 mmol). The reaction was allowed to warm to 20°C over 3 h. A mixture of 5.0 mL of NaOH (10%) and 1.5 mL of H₂O₂ (30%) was then added at 0°C and the mixture was allowed to warm to 20°C over 1 h. The reaction mixture was extracted three times with diethyl ether. The organic phases were collected, dried over Na₂SO₄ and evaporated in vacuo to afford an oil. Flash column chromatography of this crude oil (silica gel, 1:4 hexane/diethyl ether v/v) afforded the trihydroxy silyl ether 13 (70 mg, 52%) as an undetermined diastereomeric mixture.

1H NMR (CDCl₃; 500 MHz) δ: 3.62-3.48 (21H, m), 3.43-3.37 (21H, m), 1.20-0.94 (31H, m), 0.90 (3H, dd, J=6.7, 2.7 Hz), 0.88 (9H, s), 0.86 (3H, s), 0.82 (3H, s), 0.08 (3H, s), 0.05 (6H, s), 13C NMR (CDCl₃, 125 MHz) δ: 75.0, 71.9, 69.4, 68.2, 68.1, 56.2, 54.2, 53.7, 51.7, 43.0, 42.8, 41.5, 41.0, 34.0, 39.8, 37.3, 36.1, 35.6, 33.5, 32.4, 31.5, 25.8, 23.6, 22.5, 21.2, 20.9, 16.6, 13.6, 13.4, −4.7.

(3S,5S,6S,8R,9S,10R,13S,14S,17S)-3-Hydroxy-17-((S)-2-hydroxy-6-methylhept-6-en-2-yl)-10,13-dimethylhexadeca-1,5,9-triene-17-yl acetate (14, Oxy41)

To a solution of the trihydroxy silyl ether 13 (50 mg, 0.071 mmol) in anhydrous dichloromethane (2.0 mL) was added dimethylaminopyridine (14.4 mg, 0.12 mmol) followed by p-toluenesulfonfyl chloride (15 mg, 0.079 mmol). After stirring for 3 h, the reaction was treated with satd. NaHCO₃ and extracted three times with dichloromethane. The organic phases were collected, dried over Na₂SO₄ and concentrated under reduced pressure. Flash column chromatography (silica gel, 1:4 hexane/diethyl ether v/v) yielded the tosylate intermediate (35.0 mg, 70%) as a white powder. Treatment of this crude material with 5.0 mL of acetic anhydride and pyridine mixture (1:1 v/v) (70b) followed by purification via flash column chromatography (silica gel, 1:2 hexane/diethyl ether v/v) afforded the toslyoxy acetate in quantitative yield.

To a solution of the acetate intermediate (35 mg, 0.050 mmol) in anhydrous acetonitrile (3.0 mL) was added lithium iodide (60 mg, 0.45 mmol). The reaction was refluxed for 3 h. The mixture was then treated with water and extracted three times with diethyl ether. The organic phases were collected, dried over Na₂SO₄ and concentrated under reduced pressure. The crude residue was treated with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (15 mg, 0.099 mmol) in 3.0 mL of acetonitrile and refluxed for 2 h (70c). The reaction was treated with satd. NH₄Cl and extracted with diethyl ether. The organic phases were dried over Na₂SO₄ and concentrated under reduced pressure. Deprotection of the tert-butyl(dimethyl)silyl ether was performed under conditions similar to those described for the preparation of 12 to afford the alkene acetate 14 (Oxy41) in quantitative yield.

1H NMR (CDCl₃; 500 MHz) δ: 4.70-4.65 (3H, M), 3.57-3.54 (1H, m), 3.03 (3H, s), 2.01-1.71 (6L1, m), 1.61 (3H, s), 1.57-1.31 (16L1, m), 1.27 (3H, s), 1.21-0.90 (71L, m), 0.86 (3H, s), 0.83 (3H, s). 13C NMR (CDCl₃, 125 MHz) δ: 170.7, 145.7, 109.9, 72.4, 70.9, 57.6, 56.2, 53.5, 48.6, 43.4, 42.9, 40.0, 38.1, 37.4, 37.1, 36.5, 35.3, 32.1, 31.0, 29.6, 26.2, 23.6, 22.3, 22.2, 22.1, 21.2, 20.9, 13.6, 13.3.
US 9,526,737 B2

Synthesis Example 8

Oxy48

(3S,SS,6S,8R,9S,10R,13S,14S,17S)-17-((2S)-2,7-Dihydroxy-6-methylheptan-2-yl)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3,6-diol (15, [Oxy48])

Deprotection of the tert-butyl dimethylsilyl ether 13 was performed under conditions similar to those described for the preparation of 12 to afford 15 (Oxy48) in quantitative yield.

Synthesis Example 9

Oxy49


To a solution of the acetate 14 (10 mg, 0.022 mmol) in methanol (1.0 mL) was added KOH (4 mg, 0.073 mmol) and

Synthesis Example 10

Oxy28

The mixture was allowed to stir for 1 h. The solvent was then removed in vacuo to yield a crude residue which was purified by flash column chromatography (silica gel, 5% methanol in diethyl ether) to afford the alkene triol 16 (Oxy49) in quantitative yield.

$^1$H NMR (CDCl$_3$; 500 MHz) $\delta$: 3.62-3.48 (2H, m), 3.43-3.37 (2H, m), 1.20-0.94 (32H, m), 0.90 (3H, dd, J=6.7, 2.7 Hz), 0.86 (3H, s), 0.82 (3H, s), 0.08 (3H, s).

$^{13}$C NMR (CDCl$_3$, 125 MHz) $\delta$: 75.0, 71.9, 69.4, 68.2, 68.1, 56.2, 53.7, 51.7, 43.0, 42.8, 41.5, 41.0, 40.1, 39.8, 37.3, 36.1, 35.6, 33.5, 32.4, 31.5, 23.6, 22.5, 21.2, 20.9, 16.6, 13.6, 13.4.

Synthesis Example 9

Oxy49

$^1$H NMR (CDCl$_3$; 500 MHz) $\delta$: 3.62-3.48 (2H, m), 3.43-3.37 (2H, m), 1.20-0.94 (32H, m), 0.90 (3H, dd, J=6.7, 2.7 Hz), 0.86 (3H, s), 0.82 (3H, s), 0.08 (3H, s).

$^{13}$C NMR (CDCl$_3$, 125 MHz) $\delta$: 75.0, 71.9, 69.4, 68.2, 68.1, 56.2, 53.7, 51.7, 43.0, 42.8, 41.5, 41.0, 40.1, 39.8, 37.3, 36.1, 35.6, 33.5, 32.4, 31.5, 23.6, 22.5, 21.2, 20.9, 16.6, 13.6, 13.4.

Synthesis Example 10

Oxy28

$^1$H NMR (CDCl$_3$; 500 MHz) $\delta$: 4.70-4.67 (2H, m), 3.50-3.49 (1H, m), 3.45-3.35 (1H, m), 1.98-1.70 (10H, m), 1.71 (3H, s), 1.45-1.31 (10H, m), 1.25 (3H, s), 1.19-0.88 (10H, m), 0.86 (3H, s), 0.82 (3H, s).

$^{13}$C NMR (CDCl$_3$, 125 MHz) $\delta$: 145.7, 109.9, 72.4, 70.9, 57.6, 56.2, 53.5, 48.6, 43.4, 42.9, 40.0, 38.1, 37.4, 37.1, 36.5, 35.4, 32.1, 31.0, 29.6, 26.2, 23.6, 22.3, 22.2, 22.1, 21.2, 13.6, 13.3.
To a stirred solution of B1 (18.0 mg, 0.045 mmol) and imidazole (9.1 mg, 0.134 mmol) in DMF (5 mL) was added TBSCI (8.8 mg, 0.058 mmol) at 0°C. The reaction was allowed to warm to 23°C and stirred overnight. The reaction was quenched with 50% NH₄Cl (10 mL) and extracted with diethyl ether (15 mL). The combined organic layers were dried over MgSO₄, concentrated under vacuum and purified by column chromatography (33% ethyl acetate in hexane) to yield 21.3 mg (92%) of B2 as a white solid. (H NMR δ 5.31 (m, 1H), 3.48 (m, 1H), 2.31-0.83 (m, 27H), 1.77 (s, 3H), 1.00 (s, 3H), 0.89 (s, 9H), 0.87 (d, 6H, J=6.7 Hz), 0.86 (s, 3H), 0.05 (s, 6H).

To a solution of B2 (18.0 mg, 0.035 mmol) in THF (1 mL) was added 1.0 M borane in THF (0.098 mL, 0.098 mmol) at 0°C, and the reaction mixture was stirred for 14 h at 23°C. 15% aqueous sodium hydroxide solution (0.3 mL) and 30% hydrogen peroxide (0.15 mL) were added to the reaction mixture at 0°C. After being stirred for 4 h at 23°C, the reaction mixture was diluted with water and the crude product was isolated by ethyl acetate extraction. Concentration gave an oily product which was purified by flash column chromatography. Elution with 20% ethyl acetate in hexane gave alcohol B3 (11.4 mg, 61%) as a colorless oil. (H NMR δ 3.52 (m, 1H), 3.40 (m, 1H), 2.17-0.57 (m, 28H), 1.26 (s, 3H), 0.88 (s, 9H), 0.85 (s, 3H), 0.86 (s, 3H), 0.82 (s, 6H, J=8.4 Hz), 0.05 (s, 6H).

To a solution of the alcohol B3 (5.0 mg, 0.009 mmol), triethylamine (0.013 mL, 0.093 mmol) and 4-(dimethylamino)pyridine (0.01 mg, 0.001 mmol) in CH₂Cl₂ (3 mL) was added acetic anhydride (0.005 mL, 0.047 mmol). The reaction was stirred at 23°C until TLC indicated completion of the reaction. The reaction was diluted with diethyl ether (15 mL) and quenched with water (10 mL). The organic phase was separated, dried over MgSO₄, concentrated under vacuum and then purified by column chromatography (20% ethyl acetate in hexane) to give 5.0 mg (95%) of the desired acetate.

This acetate (3.0 mg, 0.005 mmol) was dissolved in methanol (1 mL). Catalytic amount of p-toluensulfonic acid (0.2 mg, 0.001 mmol) was then added and the reaction mixture was stirred at 23°C until TLC indicated completion of the reaction. The reaction was diluted with ethyl acetate (10 mL) and quenched with 5% Na₂CO₃ solution (5 mL). The organic phase was separated, dried over MgSO₄, concentrated under vacuum and then purified by column chromatography (50% ethyl acetate in hexane) to give 1.7 mg (72%) of the desired acetate B4 (Oxy28). (H NMR δ 4.68 (m, 1H), 3.55 (m, 1H), 2.17-0.57 (m, 28H), 2.03 (s, 3H), 1.26 (s, 3H), 0.87 (d, 6H, J=6.5 Hz), 0.87 (s, 3H), 0.83 (s, 3H).

**Synthesis Example 11**

Oxy51

(3S,8S,9S,10R,13S,14S,17S)-10,13-dimethyl-17-(2-methyl-1,3-dioxolan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-11H-cyclopenta[a]phenanthren-3-yl acetate (C1)

To a solution of pregnenolone acetate (11.4 g, 32 mmol) in 160 mL benzene were added pyridinium p-toluenesulfonate (1.61 g, 6.4 mmol) and ethylene glycol (5.5 mL, 6.12 g, 98.6 mmol). The mixture was refluxed under Dean-Stark apparatus at 110°C for 12 h. The reaction mixture was diluted with diethyl ether, washed with water and satd NaCl sequentially, dried over Na₂SO₄ and concentrated in vacuo. Purification of the crude solid by recrystallization in hot hexane provided acetate C1 (10 g, 78%) as colorless crystals.

[C1]

**3H NMR (CDCl₃; 400 MHz) δ**: 5.37-5.36 (1H, m), 4.63-4.56 (1H, m), 4.02-3.82 (4H, m), 2.32-2.29 (1H, m), 2.02 (3H, s), 1.87-1.43 (16H, m), 1.29 (3H, s), 1.23-1.06 (3H, m), 1.01 (3H, s), 0.77 (3H, s). 13C NMR (CDCl₃, 100 MHz) δ: 170.5, 139.7, 122.5, 112.0, 74.0, 65.2, 63.2, 58.2, 56.5, 50.0, 41.8, 39.4, 38.1, 37.0, 36.6, 31.8, 31.4, 27.8, 24.6, 23.8, 23.0, 21.4, 20.8, 19.3, 12.9.

1-((3S,5S,6S,8R,9S,10R,13S,14S,17S)-3,6-bis(tert-butyl(dimethyl)silyloxy)-10,13-dimethylhexadecahydro-11H-cyclopenta[a]phenanthren-17-yl)ethanone (C2)

To a solution of acetate C1 (5.0 g, 12 mmol) in THF (150 mL) at 0°C, was added 1.0 M BH₃ in THF (40.0 mL, 40
mmol). The reaction was allowed to warm to 20°C over 5 h. Upon completion, a mixture of 150 mL of NaOH (10%) and 75 mL of H₂O₂ (33%) was added at 0°C and allowed to warm to 20°C over 4 h. The reaction mixture was extracted three times with diethyl ether (100 mL x 3). The organic phases were collected, dried over Na₂SO₄ and evaporated in vacuo to afford an oil. The crude acetal diol (5.1 g, 13.5 mmol) was dissolved in acetone (250 mL) and treated with 1 M HCl (50 mL, 50 mmol). After 30 min under reflux, the resulting mixture was quenched with 1 M NaOH at 0°C and the organic solvent was evaporated. The aqueous layer was extracted with diethyl ether three times (50 mL x 3). The organic layer was washed with sat. NaCl, dried over Na₂SO₄, and concentrated under reduced pressure. The crude ketone (4.52 g, 12.9 mmol) was dissolved in anhydrous dimethylformamide (DMF; 50 mL) and imidazole (15.0 g, 22 mmol) was added. The reaction was allowed to stir for 20 min followed by slow addition of tert-butylidinemethylsilyl chloride (9.8 g, 65 mmol). After stirring for 12 h at ambient temperature, the reaction mixture was quenched with water and extracted three times with diethyl ether (150 mL x 3). The organic layers were washed with 1 M NaOH, dried over Na₂SO₄, and evaporated in vacuo to give an oil. Purification of the residue by column chromatography (silica gel; 5:1 hexane/diethyl ether v/v) afforded bis(tert-butylidinemethylsilyl)ketene C₂ (3.5 g, 52% over three steps) as a white powder.

NaCl. The organic phases were collected, dried over Na₂SO₄ and concentrated in vacuo to afford a crude yellow solid. Flash column chromatography (silica gel; 3:1 hexane/diethyl ether v/v) yielded bis(tert-butylidinemethylsilyl)propargyl alcohol C₃ (2.61 g, 88%) as a white powder.

To a solution of bis(tert-butylidinemethylsilyl)propargyl alcohol C₃ (200 mg, 0.33 mmol) in anhydrous tetrahydrofuran (4.0 mL) was added diisopropylethylamine (4.0 mL), 2-bromothiophene (0.1 mL, 170 mg, 1.02 mmol), Pd(PPh₃)₄ (60 mg, 0.052 mmol), and CuI (30 mg, 0.168 mmol). The reaction mixture was heated at 70°C under N₂ atmosphere for 4.5 h. Upon completion, the solvent was removed under reduced pressure followed by flash column chromatography (silica gel, 1:3 diethyl ether/hexane v/v) to afford bis(tert-butylidinemethylsilyl)thiophene C₄ (184 mg, 81%) as an off-white powder.
41

\[ 1^1 \text{H NMR (CDCl}_3; 400 \text{ MHz}) \delta: 7.19 (1H, dd, J=5.2, 1.2 Hz), 7.14 (1H, dd, J=3.6, 0.8 Hz), 6.94 (1H, dd, J=5.2, 3.6 Hz), 3.60-3.52 (1H, m), 3.44-3.38 (1H, m), 2.56 (2H, q, J=16.8 Hz), 2.11-1.49 (12H, m), 1.45 (3H, s), 1.29-0.91 (12H, m), 0.89 (18H, s), 0.84 (3H, s), 0.81 (3H, s), 0.051 (3H, s), 0.49 (3H, s), 0.038 (3H, s), 0.033 (3H, s). 13^C NMR (CDCl}_3; 100 \text{ MHz}) \delta: 131.2, 126.7, 126.1, 123.6, 90.7, 76.4, 74.3, 72.2, 70.2, 57.6, 56.2, 53.6, 51.7, 42.9, 41.7, 39.9, 37.5, 36.1, 35.1, 33.6, 33.1, 31.6, 26.9, 25.8, 23.6, 22.3, 20.9, 18.2, 17.9, 13.5, 13.4, 4.2, -4.73, -4.79, -4.84. \]


Compound C4 (80 mg, 0.90 mmol) was dissolved in 6.0 ml of THF/CH}_{2}CN (1:1 v/v) and treated with H\textsubscript{2}O\textsubscript{2} (0.1 ml). After stirring for 1 h at 20\textdegree C, the reaction was treated with water and extracted three times with diethyl ether (10 ml\times3). The combined organic layers were washed with satd. NaHCO\textsubscript{3} followed by satd. NaCl. The organic phases were collected, dried over Na\textsubscript{2}SO\textsubscript{4} and concentrated in vacuo to give an oil. Flash column chromatography of the residue (silica gel, 5% methanol/95% diethyl ether) yielded C5 (Oxy50) (37.7 mg, 69%) as a white powder.

42

and the solvent was removed under reduced pressure. The crude product (10 mg, 0.90 mmol) was dissolved in THF/CH\textsubscript{2}CN (0.6 ml, 1:1 v/v) and treated with H\textsubscript{2}O\textsubscript{2} (20 \mu l). After stirring for 1 h at 20\textdegree C, the reaction was treated with water and extracted three times with diethyl ether (10 ml\times3). The combined organic layers were washed with satd. NaHCO\textsubscript{3} followed by satd. NaCl. The organic phases were collected, dried over Na\textsubscript{2}SO\textsubscript{4} and concentrated in vacuo to give an oil. Flash column chromatography of the residue (silica gel, 5% methanol/95% diethyl ether) yielded C6 (Oxy50) (42.0 mg, 96%) as a white powder.

Synthesis Example 13

Oxy53


To a stirred suspension of magnesium turnings (1.3 g, 53.5 mmol) was added 1-bromo-3-phenylpropene (2.1 g, 10.5 mmol) in anhydrous diethyl ether (10 ml). After stirring under reflux for 30 min, the initially produced Grignard reagent was cannulated into a solution of bis(tert-butylidimethylsilyloxy) ketone C2 (300 mg, 0.53 mmol) in anhydrous THF (15 ml) and left under reflux. After 12 h, the mixture was quenched with satd. NH\textsubscript{4}Cl at 0\textdegree C. Extracted twice with diethyl ether. The organic layers were combined and washed with satd. NaCl, dried over Na\textsubscript{2}SO\textsubscript{4} and evaporated in vacuo to afford a residue, which was subjected to column chromatography on silica gel. Elution with hexane-diethyl ether (5:1 v/v) afforded the alcohol (200 mg, 55%) followed by desilylation with HF/pyridine (0.24 ml) in THF/CH\textsubscript{2}CN (12 ml, 1:1 v/v). After stir for 1 h at 20\textdegree C, the reaction was treated with water and extracted three times with diethyl ether (10 ml\times3). The organic layers were combined and washed with satd. NaHCO\textsubscript{3} followed by satd. NaCl. The organic phases were collected, dried over Na\textsubscript{2}SO\textsubscript{4} and concentrated in vacuo to give an oil. Flash column chromatography (silica gel, 5% methanol/95% diethyl ether) yielded triol C7 (Oxy53) (100 mg, 76%) as a white powder.
The stereoselective synthesis of the compound Oxy20 was carried out according to published procedures (72). The silylated pregnenolone was subjected to stereoselective addition of the anion of silylated 1-pentynyl formed by reaction of the acetylene with n-butyllithium to provide the propargylic alcohol in 84% yield. Hydrogenation of the resulting propargylic alcohol in the presence of Lindlar catalyst gave a mixture of the (Z)- and (E)-allylic alcohols (90:10). Both isomers were separated chromatographically to afford the (Z)-isomer in 68% yield and the (E)-isomer in 7% yield. The minor (E)-isomer (100 mg, 0.19 mmol) was desilylated in the presence of tetrabutylammonium fluoride in THF (0.8 mL, 0.8 mmol) to give the corresponding diol Oxy20 (70 mg, 89%) as a white powder.

1H NMR (CDCl₃; 400 MHz) δ: 7.29-7.25 (2H, m), 7.19-7.16 (3H, m), 3.61-3.53 (1H, m), 3.44-3.38 (1H, m), 2.64-2.52 (2H, m), 2.21-2.19 (19H, m), 1.25 (3H, s), 1.32-0.88 (9H, m), 0.82 (3H, s), 0.81 (3H, s), 13C NMR (CDCl₃, 100 MHz) δ: 142.5, 128.4, 128.3, 125.8, 75.1, 71.2, 69.4, 57.7, 56.3, 53.7, 51.7, 43.6, 42.9, 41.5, 40.2, 37.3, 36.5, 36.3, 33.6, 32.3, 31.0, 26.4, 23.7, 22.3, 21.9, 21.0, 13.7, 13.5.

Synthesis Example 14

Oxy52


The Grignard addition to bis(2-tert-butyldimethylsiloxy)ketone C2 (300 mg, 0.53 mmol) with (2-bromoethyl)benzene (940 mg, 5.1 mmol) in 5.0 mL of anhydrous diethyl ether in the presence of magnesium turnings (620 mg, 25.5 mmol) was performed under similar conditions as described for the preparation of Oxy53 followed by desilylation as above with 1HF/pyr to afford C8 (Oxy52) (200.0 mg, 86% over 2 steps) as a white powder.

1H NMR (CDCl₃; 400 MHz) δ: 5.56 (1H, d, J=15.5 Hz), 5.51 (1H, d, J=15.5, 6.5 Hz), 5.35-5.33 (1H, m), 3.55-3.47 (1H, m), 2.28-1.81 (6H, m), 1.66-1.38 (13H, m), 1.32 (3H, s), 1.23-1.07 (4H, m), 1.00 (3H, s), 0.98-0.90 (2H, m), 0.87 (6H, d, J=6.6 Hz), 0.82 (3H, s). 13C NMR (CDCl₃, 100 MHz) δ: 140.8, 139.1, 125.0, 121.6, 75.4, 71.8, 59.9, 56.8, 50.1, 42.8, 42.3, 41.7, 40.2, 37.2, 36.5, 31.8, 31.7, 31.3, 29.2, 28.5, 23.9, 23.3, 22.4, 22.3, 20.9, 19.4, 13.8.

Aspects of Bioactive/Pharmaceutical Compositions

Formulations or compositions suitable for oral administration can consist of liquid solutions, such as an effective amount of an oxysterol dissolved in diluents, such as water, saline, or fruit juice; capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as solid, granules or freeze-dried cells; solutions or suspensions in an aqueous liquid; and oil-in-water emulsions or water-in-oil emulsions. Tablet forms can include one or more of lactose, mannitol, corn starch, potato starch, microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, maintaining agents, preservatives, flavoring agents, and pharmaceutically compatible carriers. Suitable formulations for oral delivery can also be incorporated into synthetic and natural polymeric microspheres, or other means to protect the agents of the present invention from degradation within the gastrointestinal tract.

Formulations suitable for parenteral administration (e.g., intravenous) include aqueous and non-aqueous, isotonic
sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. The formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (i.e., lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.

The oxyesters of the present disclosure, alone or in combination with other therapeutic agents, can be made into aerosol formulations to be administered via inhalation. These aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.

Oxyesters, alone or in combination with other therapeutic agents, can also be made into formulations for transdermal application and absorption. Transdermal electroporation or iontophoresis can also be used to promote and/or control the systemic delivery of the agents and/or pharmaceutical compositions of the present invention through the skin (73).

Suitable formulations for topical administration include lozenges comprising the active ingredient in a sugar, usually sucrose and saccharin or tragacanth; pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and saccharin; mouthwashes comprising the active ingredient in a suitable liquid carrier; or creams, emulsions, suspensions, solutions, gels, creams, pastes, foams, lubricants, sprays, suppositories, or the like.

A person skilled in the art will appreciate that a suitable or appropriate formulation can be selected, adapted or developed based upon the particular application at hand. In addition, the pharmaceutical compositions of the present invention may be prepared for administration by a variety of different routes, whether systemic, local, or both. Such examples include, but are not limited to, administrations performed intraocularly, intracranially, intradermally, intrahypertically, intramuscularly, intracutaneously, intraperitoneally, intrathecally, intravenously, subcutaneously, transdermally, or directly into atherosclerotic site, such as by direct injection, direct application, and/or by implanting a device into an artery or other appropriate tissue site.

An oxyester may be formulated as to be contained within, or, adapted to release by a surgical or medical device or implant. In certain aspects, an implant may be coated or otherwise treated with an oxyester. For example, hydrogels, or other polymers, such as biocompatible and/or biodegradable polymers, may be used to coat an implant with the compositions of the present invention (i.e., the composition may be adapted for use with a medical device by using a hydrogel or other polymer). Polymers and copolymers for coating medical devices with an agent are well-known in the art. Examples of implants include, but are not limited to, angioplasty balloons, stents, drug-eluting stents, sutures, prosthesis, vascular catheters, dialysis catheters, vascular grafts, prosthetic heart valves, cardiac pacemakers, implantable cardiac defibrillators or IV needles. Merely by way of example, a stent or stent graft typically includes a slender fabric tubular graft portion and is normally used to reinforce or strengthen a weak spot in a body passageway, such as a blood vessel. Insertion of a stent graft may be performed by use of a catheter. Placement may be facilitated by balloon expansion, such as during or following a balloon angioplasty procedure, or, alternatively, the stent graft may be self-expanding.

Dosages for oxyesters of the invention can be in unit dosage form, such as a tablet or capsule. The term “unit dosage form,” as used herein, refers to physically discrete units suitable as unitary dosages for animal (e.g., human) subjects, each unit containing a predetermined quantity of the agent of the invention, alone or in combination with other therapeutic agents, calculated in an amount sufficient to produce the desired effect in association with a pharmaceutically acceptable diluent, carrier, or vehicle.

One skilled in the art can readily determine the appropriate dose, schedule, and method of administration for the exact formulation of the composition being used, in order to achieve the desired effective amount of effective concentration of the agent in the individual patient. One skilled in the art can also readily determine and use an appropriate indicator of the “effective concentration” of the compounds, for example, the oxyesters, of the present invention by a direct or indirect analysis of appropriate patient samples (e.g., blood and/or tissues), in addition to analyzing the appropriate clinical symptoms of the disease, disorder, or condition. The dose of an oxyester, or composition thereof, administered to an animal or mammal, particularly a human, in the context of the present invention should be sufficient to effect at least a therapeutic response in the individual over a reasonable time frame. The exact amount of the dose will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the severity or mechanism of any disorder being treated, the particular agent, or vehicle used, its mode of administration and the like. The dose used to achieve a desired concentration in vivo will be determined by the potency of the particular oxyester employed, the pharmacodynamics associated with the oxyester in the host, with or without additional agents, the severity of the disease state of infected individuals, as well as, in the case of systemic administration, the body weight and age of the individual. The size of the dose may also be determined by the existence of any adverse side effects that may accompany the particular agent, or composition thereof, employed. It is generally desirable, whenever possible, to keep adverse side effects to a minimum.

For example, a dose can be administered in the range of from about 5 ng (nanograms) to about 1000 mg (milligrams), or from about 100 ng to about 600 mg, or from about 1 mg to about 500 mg, or from about 20 mg to about 400 mg. For example, the dose can be selected to achieve a dose to body weight ratio of from about 0.0001 mg/kg to about 1500 mg/kg, or from about 1 mg/kg to about 1000 mg/kg, or from about 5 mg/kg to about 150 mg/kg, or from about 20 mg/kg to about 100 mg/kg. For example, a dosage unit can be in the range of from about 1 mg to about 5000 mg, or from about 5 mg to about 1000 mg, or from about 100 mg to about 600 mg, or from about 1 mg to about 500 mg, or from about 20 mg to about 400 mg, or from about 40 mg to about 200 mg of a compound according to the present invention.

A dose can be administered once per day, twice per day, four times per day, or more than four times per day as required to elicit a desired therapeutic effect. For example, a dose administration regimen can be selected to achieve a blood serum concentration of a compound of the present invention in the range of from about 0.01 to about 1000 nM, or from about 0.1 to about 750 nM, or from about 1 to about 500 nM, or from about 20 to about 500 nM, or from about 100 to about 500 nM, or from about 200 to about 400 nM. For example, a dose administration regimen can be selected
to achieve an average blood serum concentration with a half maximum dose of a compound of the present invention in the range of from about 1 μg/L (microgram per liter) to about 2000 μg/L, or from about 2 μg/L to about 1000 μg/L, or from about 5 μg/L to about 500 μg/L, or from about 10 μg/L to about 400 μg/L, or from about 20 μg/L to about 200 μg/L, or from about 40 μg/L to about 100 μg/L.

A therapeutically effective dose of an oystersterol as described herein may include one which has a positive clinical effect on a patient as measured by the ability of the agent to improve atherosclerosis, or other related cardiovascular diseases or conditions. A therapeutically effective dose of an oystersterol may also include one which has a positive clinical effect on reducing the risk of developing atherosclerosis, or other related conditions. The therapeutically effective dose of each agent can be modulated to achieve the desired clinical effect, while minimizing negative side effects. The dosage of the agent may be selected for an individual patient depending upon the route of administration, severity of the disease, age and weight of the patient, other medications the patient is taking and other factors normally considered by an attending physician, when determining an individual regimen and dose level appropriate for a particular patient.

By way of example, the invention may include elevating endogenous circulating oystersterol levels over the patient’s basal level. In a normal adult levels are about 10-400 ng/ml depending on age and type of oystersterol, as measured by mass spectrometry. Those skilled in the art of pharmacology would be able to select a dose and monitor the same to determine if an increase circulating levels over basal levels has occurred.

When given in combined therapy, the other agent can be given at the same time as the oystersterol, or the dosing can be staggered as desired. The two (or more) drugs also can be combined in a composition. Doses of each can be less when used in combination than when either is used alone. Certain embodiments may also include treatment with an additional agent which acts independently or synergistically with an oystersterol to improve vascular condition.

Oystersterols may also be administered to cells and tissues and subjects at risk of atherosclerosis, in dosages and by routes effective to reduce, eliminate, prevent, or treat atherosclerotic lesions. Another embodiment of the invention is a kit useful for any of the methods disclosed herein, either in vitro or in vivo. Such a kit can comprise one or more of the oystersterols or pharmaceutical compositions discussed herein. Optionally, the kits comprise instructions for performing the method. Optional elements of a kit of the invention include suitable buffers, pharmaceutically acceptable carriers, or the like, containers, or packaging materials. The reagents of the kit may be in containers in which the reagents are stable, e.g., in lyophilized form or stabilized liquids. The reagents may also be in single use form, e.g., in single dosage form. A skilled worker will recognize components of kits suitable for carrying out any of the methods of the invention.

The embodiments illustrated and discussed in this specification are intended only to teach those skilled in the art the best way known to the inventors to make and use the invention. Nothing in this specification should be considered as limiting the scope of the present invention. All examples presented are representative and non-limiting. The above-described embodiments of the invention may be modified or varied, without departing from the invention, as appreciated by those skilled in the art in light of the above teachings. It is therefore to be understood that, within the scope of the claims and their equivalents, the invention may be practiced otherwise than as specifically described.

REFERENCES

49


35. Day T F, Guo X, Garrett-Beal L, Yang Y. 2005. Wnt/β-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Develop Cell 8:739-750.


60. Velgova, H Cerny, Vlacav; Soma, Frantisek; Slama, Karel. Steroids. CXXVI. Further compounds with anti-sclerotization effect on *Pyrrhocoris apterus* larvae; structure and activity correlations. Collection of Czechoslovak Chemical Communications (1969), 34(11), 3354-76.

65. Sheik, Youmns M; Djerassi, Carl. Mass spectrometry in structural and stereochemical problems. CXXXII. Preparation of 5a,20α and 5a,17α,20α-cholestane-3β,6α,9Δ-diols. Electron impact induced fragmentation of steroidal Δ 17(20), Δ 20(21) and Δ 20(22) olefins. Journal of Organic Chemistry (1973), 38(20), 3545-53.


SEQUENCE LISTING

```
160> NUMBER OF SEQ ID NOS: 12
210> SEQ ID NO 1
211> LENGTH: 22
212> TYPE: DNA
213> ORGANISM: Artificial Sequence
220> FEATURE:
223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

400> SEQUENCE: 1

ttctctggct ccaccagatgc cc
```
<400> SEQUENCE: 2
taccttatg cctctctgt tg
22

<210> SEQ ID NO: 3
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 3
gagccgag ccacagag a
21

<210> SEQ ID NO: 4
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 4
cggcccag gcgcagac
19

<210> SEQ ID NO: 5
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 5
gcaccatc tcctcaacga c
21

<210> SEQ ID NO: 6
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 6
tcacaagct ccaacatcc
19

<210> SEQ ID NO: 7
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 7
gagacacc gcgaagatg
20

<210> SEQ ID NO: 8
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 8
We claim:
1. A compound having Formula I,

(Formula I)

wherein M is selected from the group consisting of hydrogen (—H), hydroxy (—OH), formoxy (—O(C==O)H), acyloxy (—O(C==O)—C<sub>1</sub>-alkyl), alkoxy (—O—C<sub>1</sub>-alkyl), sulfhydryl (—SH), alkylthio (—S—C<sub>1</sub>-alkyl), amino (—NH<sub>2</sub>), methylamino (—NHCH<sub>3</sub>), alkylamino (—NH—C<sub>1</sub>-alkyl), formamido (—NH(C==O)H), acetamido (—NH(C==O)CH<sub>3</sub>), and alkylamido (—NH(C==O)—C<sub>1</sub>-alkyl), wherein E is C<sub>1</sub>-alkyl, wherein R<sub>1</sub> is selected from the group consisting of C<sub>2</sub>-alkyl, C<sub>2</sub>-alkenyl, C<sub>8</sub>-12 alkenyl, phenylalkyl, thiophene-substituted C<sub>5</sub>-11 alkyl, C<sub>5</sub>-12 aralkenyl, C<sub>5</sub>-12 aralkynyl, halogen-substituted C<sub>6</sub>-12 aralkyl, halogen-substituted C<sub>6</sub>-12 aralkenyl, halogen-substituted C<sub>5</sub>-12 aralkynyl, alkyl-substituted C<sub>6</sub>-12 aralkyl alkyl-substituted C<sub>6</sub>-12 aralkenyl alkyl-substituted C<sub>6</sub>-12 aralkynyl hydroxy-substituted C<sub>6</sub>-12 aralkyl, and hydroxy-substituted C<sub>2</sub>-alkenyl, wherein when q is a single bond, M is hydroxy, and E is methyl, then R<sub>2</sub> is not 4-methylpentyl vinyl, 1-hy-
droxy-4-methylpentyl, 3-hydroxy-3-methylbutyl, 4-hydroxy-4-methylpentyl, 1,4-dihydroxy-4-methylpentyl, 1,5-dihydroxy-4-methylpentyl, or 2-phenylethynyl, wherein when q is a single bond, M is hydroxy, and E is methyl, then R₂ is not 4-methylpentyl or 4-methylpent-3-enyl,

wherein when q is a double bond, M is hydrogen, and E is methyl, then R₂ is not ethyl, vinyl, n-propyl, allyl, 1-propenyl, n-butyl, t-butyl, 1-methylpropyl, n-pentyl, 3-methylbutyl, 3-methylpentyl, 4-methylpentyl, 4-methylpent-3-enyl, 4-methylpent-4-enyl, 1-hydroxy-4-methylpentyl, 4-hydroxy-4-methylpentyl, 4-hydroxy-4-methylpent-1-enyl, 4-hydroxy-4-methylpent-2-enyl, 1,4-dihydroxy-4-methylpentyl, 1-(2-pyridinyl)ethyl, or 3-methyl-4-hydroxybutyl,

wherein when q is a double bond, M is hydrogen, and E is 4-methylpentyl, then R₂ is not hydroxymethyl,

wherein when q is a double bond and M is hydrogen, then R₂ is not methyl-substituted benzyl,

wherein the compound is not

and

wherein the compound is inductive of a biological response in a mammalian cell, the response selected from the group consisting of stimulated osteoblastic differentiation, inhibited adipocyte differentiation, stimulated cartilage formation, stimulated hair growth, and/or stimulated angiogenesis.

2. The compound of claim 1,

wherein the compound is selected from the group consisting of
3. A bioactive composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
4. The bioactive composition of claim 3, further comprising at least one additional agent, selected from the group consisting of parathyroid hormone, sodium fluoride, insulin-like growth factor I (IGF-I), insulin-like growth factor II (IGF-II), transforming growth factor beta (TGF-β), a cytochrome P450 inhibitor, an osteogenic protein, bone morphogenetic protein 2 (BMP 2), bone morphogenetic protein 4 (BMP 4), bone morphogenetic protein 7 (BMP 7), and bone morphogenetic protein 14 (BMP 14).
5. The compound of claim 1, wherein q is a single bond.
6. The compound of claim 5, wherein E is —CH₂—.
7. The compound of claim 6, wherein M is —OH or —O—(C=O)CH₃.
8. The compound of claim 7, wherein Rₘ is selected from the group consisting of C₆₋₉ alkyl, C₃₋₅ alkyl, C₉₋₁₂ phenylalkyl, thiophene-substituted C₆₋₁₁ alkyl, C₉₋₁₂ aralkyl, and hydroxy-substituted C₆ alkyl.
9. The compound of claim 8, wherein the compound is

10. The compound of claim 8, wherein the compound is
11. The compound of claim 1, wherein q is a double bond.
12. The compound of claim 11, wherein E is —CH₂—.
13. The compound of claim 12, wherein M is hydrogen.
14. The compound of claim 13, wherein R₂ is selected from the group consisting of C₂-C₅ alkenyl, C₆-C₁₂ phenalkyl, thiophene-substituted C₅-C₁₀ alkyl, C₅-C₁₂ aralkynyl, and halogen-substituted C₄-C₁₂ aralkyl.